



05-05-2017

12:00 - 13:00	Industry Satellite Symposium 1	Room A
13:00 - 13:30	Welcome reception	Main foyer
13:30 - 13:45	Opening and welcome Chair: M. Reck, DE; A. Nicholson, GB	Room B
14:30 - 16:00	Management of brain metastases Chair: S. Ekman, SE; D. De Ruyscher, NL	Room B
14:30 - 14:50	Molecular characteristics of brain metastases: Are they different? <u>S. Ekman</u> , SE	
14:50 - 15:10	Systemic treatment of brain metastases <u>J.C.-H. Yang</u> , TW	
15:10 - 15:30	Local management of brain metastases: The Surgeon's perspective <u>M. De Praeter</u> , BE	
15:30 - 15:50	Radiation therapy of brain metastases <u>J. Zindler</u> , NL	
15:50 - 16:00	Questions and Answers	



14:30 - 16:00	The implications of TNM staging on clinical practice (in NSCLC) Chair: <u>T. Mitsudomi</u> , JP	Room A
14:30 - 14:50	The impact on bronchoscopic staging <u>F.J.F. Herth</u> , DE	
14:50 - 15:10	Surgical implications <u>T. Mitsudomi</u> , JP	
15:10 - 15:30	M1b: Will it be useful to establish a new paradigm of oligometastatic disease? <u>W. Eberhardt</u> , DE	
15:30 - 15:50	Combination of molecular markers and TNM staging to refine prognosis and therapy <u>M. Tsao</u> , ON/CA	
15:50 - 16:00	Questions and Answers	
16:00 - 16:30	Coffee break	Hall 1
16:30 - 18:00	Immunotherapy of non-small cell lung cancer Chair: <u>N. Rizvi</u> , US; <u>S. Peters</u> , CH	Room B
16:30 - 16:50	First-line treatment <u>M. Reck</u> , DE	
16:50 - 17:10	Biomarkers <u>K. Kerr</u> , GB	
17:10 - 17:30	Combination approaches <u>N. Rizvi</u> , US	
17:30 - 17:50	Toxicities of immuno-checkpoint blockers <u>J.-C. Soria</u> , FR	
17:50 - 18:00	Questions and Answers	



16:30 - 18:00 Management of dyspnoea and cachexia in lung cancer Room A
Chair: R. Gralla, US; D. Heigener, DE

16:30 - 16:50 Causes of dyspnoea in lung cancer and interventional management
D. Heigener, DE

16:50 - 17:10 Medical management of dyspnoea
S. Simon, DE

17:10 - 17:30 Pain management
M. Di Palma, FR

17:30 - 17:50 Cachexia
R. Gralla, US

17:50 - 18:00 Questions and Answers

18:30 - 20:00 Industry Satellite Symposium 2 Room A

06-05-2017

08:00 - 08:50 Lung cancer presenting through the emergency room Room A
Chair: M. Callister, GB; T. Newsom-Davies, GB

08:00 - 08:15 Is emergency presentation of lung cancer a problem?
T. Newsom-Davies, GB

08:15 - 08:30 Why does lung cancer present through the emergency room and how can outcomes be improved?
M. Callister, GB

08:30 - 08:50 Discussion



08:00 - 08:50	How to classify progressive disease and clinical consequences: Definition and implication of progression Chair: H. Prosch, AT; R. Califano, GB	Room W
08:00 - 08:15	The view of the Radiologist <u>H. Prosch</u> , AT	
08:15 - 08:30	The view of the Oncologist <u>R. Califano</u> , GB	
08:30 - 08:50	Discussion	
08:00 - 08:50	Will immunotherapy be the standard of care in lung cancer? Chair: J. Remon, ES; G. Mountzios, GR	Room X
08:00 - 08:20	The role of immunotherapy in small cell lung cancer and other thoracic tumours <u>J. Remon</u> , ES	
08:20 - 08:40	Does immunotherapy apply for all NSCLC patients? <u>G. Mountzios</u> , GR	
08:40 - 08:50	Discussion	
09:00 - 10:30	Immunotherapy for other thoracic tumours Chair: G. Giaccone, US; S. Popat, GB	Room B
09:00 - 09:20	Perspectives in SCLC <u>S. Peters</u> , CH	
09:20 - 09:40	Realities in mesothelioma <u>S. Popat</u> , GB	
09:40 - 10:00	Thymic tumours <u>G. Giaccone</u> , US	
10:00 - 10:20	T cell therapies <u>A.-M. Dingemans</u> , NL	
10:20 - 10:30	Questions and Answers	



09:15 - 10:15	Should we use newer generation targeted treatment upfront? Chair: T.S.K. Mok, CN	Room A
09:15 - 09:25	Introduction and first vote	
09:25 - 09:45	Yes <u>D. Carbone</u> , US	
09:45 - 10:05	No <u>F. Barlesi</u> , FR	
10:05 - 10:15	Second vote and conclusions	
10:30 - 11:00	Coffee break	Hall 1
11:00 - 12:30	Management of non-oncogene driven NSCLC Chair: W. Eberhardt, DE; M.J. Ahn, KR	Room B
11:00 - 11:20	The revival of antiangiogenic therapies <u>R. Garcia Campelo</u> , ES	
11:20 - 11:40	Anti-EGFR therapies in unselected NSCLC patients <u>L. Paz-Ares</u> , ES	
11:40 - 12:00	Second line treatment and beyond: Selecting new agents in the arena for subsequent therapy <u>L. Horn</u> , US	
12:00 - 12:20	Elderly and frail patients: Choosing the optimal treatment option <u>M.J. Ahn</u> , KR	
12:20 - 12:30	Questions and Answers / Panel Discussion	



11:00 - 12:30 The role of the pathologist in guiding therapy Room A
Chair: K. Kerr, GB; S. Lantuejoul, FR

11:00 - 11:20 Conventional therapy for lung cancer
M. Tsao, ON/CA

11:20 - 11:40 Targeted therapy for lung cancer
S. Lantuejoul, FR

11:40 - 12:00 Immunomodulatory therapy for lung cancer
F.R. Hirsch, US

12:00 - 12:20 Therapy for mesothelioma and other thoracic malignancies
A. Nicholson, GB

12:20 - 12:30 Questions and Answers / Panel Discussion

11:00 - 12:30 Prevention and smoking cessation Room C
Chair: P. Boffetta, US; V. Westeel, FR

11:00 - 11:20 Smoking and the risk of early lung cancer
H. Ashraf, NO

11:20 - 11:40 The environmental factors we should address to reduce the incidence of lung cancer in non-smokers
P. Boffetta, US

11:40 - 12:00 The e-cigarette: New data with longer follow-up
A. Stoebner-Delbarre, FR

12:00 - 12:20 Does smoking cessation improve survival in metastatic lung cancer?
V. Westeel, FR

12:20 - 12:30 Questions and Answers / Panel Discussion



11:00 - 12:30	Standards for high-dose radiotherapy in lung cancer Chair: S. Senan, NL; D. De Ruyscher, NL	Room W
11:00 - 11:20	ESTRO practice guidelines for lung SABR delivery <u>S. Senan</u> , NL	
11:20 - 11:40	Evidence-based guidelines for delivery of curative radiotherapy in stage III NSCLC <u>R. Dziadziuszko</u> , PL	
11:40 - 12:00	ESTRO practice guidelines for combining radiotherapy with targeted agents <u>D. De Ruyscher</u> , NL	
12:00 - 12:20	Extra-cranial oligometastatic NSCLC: Techniques, doses and timing <u>G. Hanna</u> , GB	
12:20 - 12:30	Questions and Answers / Panel Discussion	
11:00 - 12:30	Rare thoracic malignancies Chair: P. Van Schil, BE; F. Melfi, IT	Room X
11:00 - 11:20	Isolated lung perfusion for pulmonary metastases from sarcoma <u>P. Van Schil</u> , BE	
11:20 - 11:40	Local control in primary sarcoma of the chest wall <u>K. Wiebe</u> , DE	
11:40 - 12:00	Robotic extended thymectomy for early stage thymoma <u>F. Melfi</u> , IT	
12:00 - 12:20	Diagnostic workup and treatment of bronchopulmonary carcinoid tumours <u>S. Schmid</u> , DE	
12:20 - 12:30	Questions and Answers / Panel Discussion	
12:30 - 13:00	Poster Display session	Hall 1
12:30 - 12:30	Tumour biology and pathology	
12:30 - 12:30	4P - PD-L1 in NSCLC cytology <u>M. Kovacevic</u> , I. Kern, S. Gabrič; SI	



- 12:30 - 12:30 5P - Repeated biopsy for mutational analysis on EGFR-mutated non-small cell lung cancer (EGFR-NSCLC): feasibility and safety
G. Anguera, M. Riudavets, A. Torrego, V. Pajares, A. Gimenez, L. López-Vilaró, E. Martínez, J.C. Trujillo-Reyes, E. Lerma, M. Majem; ES
- 12:30 - 12:30 6P - Metformin sensitizes lung cancer cells to treatment by the Tyrosine Kinase Inhibitor erlotinib
X. Wang, Y. Xiang, B. Gao; CN
- 12:30 - 12:30 7P - Population-level effect of targeted therapy in patients with advanced pulmonary adenocarcinoma: a Swiss prospective cohort study
C. Schwegler, D. Kaufmann, O. Gautschi, S. Aebi, J. Diebold, D. Pfeiffer; CH
- 12:30 - 12:30 8P - Expression of genes associated with anti-viral response in EGFR mutant non-small-cell lung cancer (NSCLC).
N. Karachaliou¹, A. Giménez-Capitán¹, A. Drozdowskyj¹, E. Aldeguer¹, M. González Cao¹, A.F. Cardona², G. López-Vivanco¹, J.M. Sánchez¹, M. Gil¹, R. Rosell¹; ¹ES, ²CO
- 12:30 - 12:30 9P - Knockdown of MFN2 gene expression inhibits lung adenocarcinoma cell proliferation
Y. Lou, Y. Zhang, J. Xu, P. Gu, W. Zhang, X. Zhang, H. Zhong, L. Jiang, B. Han; CN
- 12:30 - 12:30 10P - In Vivo Evaluation of Combretastatin A-4 Phosphate for lung cancer by Bioluminescence Imaging and Multispectral Optoacoustic Tomography
L. Liu, S. Kumari, J. Campbell, R. Mason, L. Zhang; TX/US
- 12:30 - 12:30 11P - Prognostic significance of different immunohistochemical markers in small cell lung cancer
E. Gkika, S. Beitingger, S. Adebahr, T. Schimek-Jasch, S. Wiesemann, C. Waller, A. Grosu, U. Nestle, G. Kayser; DE
- 12:30 - 12:30 12P - Thyroid transcription factor-1 as a prognosticator in patients with metastatic lung adenocarcinoma without EGFR sensitizing mutations
J.Y. Park, S.H. Jang, J.-H. Kim, S. Park, Y.I. Hwang, K.-S. Jung, J.W. Seo; KR
- 12:30 - 12:30 13P - Characterizing the DNA damage response in putative stem cells of resected normal lung and matched NSCLC patient samples
T. Marti, C. Tièche, R. Peng, S. Hall, L. Froment, P. Dorn, S. Berezowska, R. Schmid; CH
- 12:30 - 12:30 14P - Histone H2AX phosphorylation increases apoptosis of lung cancer cells by miR-3196/PUMA pathway
C. Lu, C. Xu, L. Zhang, L. Duan; CN
- 12:30 - 12:30 15P - PLGF regulates crosstalk between non-small cell lung cancer cells and tumor-associated macrophages in cancer vascularization and growth
W. Zhang, Y. Lou, B. Yan, Y. Zhao, S. Cui, L. Jiang, B. Han; CN
- 12:30 - 12:30 16P - Carvacrol induces growth inhibition and circumvents chemoresistance via inhibition of STAT3/Skp2/p27 pathway in non-small lung cancer cells.
K.-C. Kim, C. Lee; KR
- 12:30 - 12:30 Prevention, Early detection, Epidemiology, Tobacco control



- 12:30 - 12:30 19P - Domestic Cooking Fuel as a Risk Factor for Lung Cancer in Women - A Case control study
S. Katpattil, IN
- 12:30 - 12:30 21P - The efficacy of combination therapy with Varenicline and Bupropion for smoking cessation.
D. Johns, IN
- 12:30 - 12:30 23P - Pictorial warning on cigarette packets and its role in tobacco cessation- questionnaire survey among cigarette smokers in Chennai.
C.J.K. Francis, IN
- 12:30 - 12:30 25P - Tobacco Consumption Pattern among Auto Rickshaw Drivers in Chennai City, Tamil Nadu, India
D.L. Francis, IN
- 12:30 - 12:30 26P - Smoking habits and awareness about anti-smoking acts among General Public in Gurgaon, Haryana, India.
C.J.K. Francis, IN
- 12:30 - 12:30 27P - Factors causing treatment delays and its impact on treatment outcome in patients of lung cancer-an analysis.
D. Kumar, S. Singh; IN
- 12:30 - 12:30 28P - Impact of a pharmaceutical consultation, review of a pilot study
E. Clou, J. Gaudas, K. Ahmed, D. Avenin, A. Estes, G. Galula, J. Fillon, J.P. Lotz, I. Debrix; FR
- 12:30 - 12:30 29P - Baseline Characteristics of Participants in PL-208: A Multi-Center Trial of the ProLung Test™ (Transthoracic Bioconductance Measurement) as an Adjunct to CT Chest Scans for the Risk Stratification of Patients with Pulmonary Lesions Suspicious for Lung Cancer
R. Yung¹, D. Ost², M. Simoff³, C. Reddy⁴, A. Goyal⁵, I. Barjakarevic⁶, M. Garff⁴, K. Larson⁴, J. O'Driscoll⁴, S. Makani⁶; ¹MD/US, ²TX/US, ³MI/US, ⁴UT/US, ⁵IL/US, ⁶CA/US
- 12:30 - 12:30 Translational research
- 12:30 - 12:30 31P - Targeted therapy for patients with ALK positive NSCLC: results from the transalpine cohort
C. Britschgi¹, M. Rechsteiner¹, R. Delaloye¹, M. Früh¹, G. Metro², O. Gautschi¹, S. Rothschild¹, R. Stahel¹, P. Wild¹, A. Curioni-Fontecedro¹; ¹CH, ²IT
- 12:30 - 12:30 32P - Effects of BTK inhibitor on gefitinib-resistance non-small cell lung cancer
T.-M. Hong, Y.-T. Fang, Y.-L. Chen; TW
- 12:30 - 12:30 33P - The screening and characterization of aptamer against gefitinib resistant cells
Y.-L. Chen, J.-E. Wu, T.-M. Hong; TW
- 12:30 - 12:30 34P - Discovery of 1,3,5-triazine-monastrol based novel EGFR-tyrosine kinase inhibitor against human lung carcinoma



U. Singh, J. Shrivastava, A. Verma, H. Bhat; IN

- 12:30 - 12:30 35P - CDK7 inhibition as a promising therapeutic strategy in lung squamous cell carcinoma with SOX2 amplification
J.C. Lee, J.Y. Hur, J.K. Rho, H.R. Kim, C.-M. Choi; KR
- 12:30 - 12:30 36P - Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab
F. Passiglia, A. Perez, A. Listì, M. Castiglia, E. Musso, C. Ancona, S. Rizzo, M. Alù, L. Blasi, A. Russo; IT
- 12:30 - 12:30 37P - Can we perform subtyping of non-small cell lung cancer patients by use of lung tissue metabolic fingerprinting?
M. Ciborowski, J. Kisluk, K. Pietrowska, P. Samczuk, E. Parfieniuk, T. Kowalczyk, M. Kozłowski, A. Kretowski, J. Niklinski; PL
- 12:30 - 12:30 38P - Flow cytometry immunophenotyping of pleural fluid cytology in patients with diffuse large B-cell lymphoma (DLBCL) and malignant pleural effusion
F. Lumachi, P. Ubiali, R. Tozzoli, S. Sulfaro, S. Basso; IT
- 12:30 - 12:30 39P - Efficacy of Tumor Treating Fields (TTFields) and anti-PD-1 in non-small-cell lung cancer (NSCLC) preclinical models
U. Weinberg¹, T. Voloshin², O. Yitzaki², N. Kaynan², M. Giladi², A. Shteingauz², M. Munster², S. Cahal², E. Kirson², Y. Palti²; ¹CH, ²IL
- 12:30 - 12:30 40P - Antitumoral effect and reduced systemic toxicity in mice after intra-tumoral injection of an in vivo solidifying calcium sulfate formulation with docetaxel
M. Sandelin, S. Grudén, V. Rasanen, P. Micke, M. Hedeland, N. Axén, M. Jeansson; SE
- 12:30 - 12:30 41P - Development of novel 1,2,4--triazole--thiol derivatives as dual PI3K/mTOR inhibitor against the non-small cell lung cancer (NSCLC)
A. Verma, V. Kumar, U. Singh; IN
- 12:30 - 12:30 42P - Dual inhibitory effects of novel Naringenin analogue in tobacco-carcinogen induced lung cancer via inhibition of PI3K/Akt/mTOR pathway
V. Kumar, A. Verma, P. Bhatt; IN
- 12:30 - 12:30 43P - A phase I-II clinical trial to evaluate the safety, pharmacokinetics and efficacy of high dose intravenous ascorbic acid synergy with mEHT in Chinese patients with stage III-IV Non-Small Cell Lung Cancer
J. Ou, X. Zhu, Y. Lu, C. Zhao, H. Zhang, X. Gui, X. Wang, X. Zhang, T. Zhang, C.L.K. Pang; CN
- 12:30 - 12:30 Imaging and staging
- 12:30 - 12:30 47P - Multi Detector CT evaluation of suspicious malignant lung masses with its Combined wash-in & wash-out features and their histopathological correlation
S. Khanduri, S. Bhagat; IN
- 12:30 - 12:30 48P - Evaluation of Neoplasms Incidentally Detected by Preoperative FDG-PET/CT for Primary Lung Cancer.



Y. Noda, H. Matsudaira, S. Arakawa, K. Yoshida, T. Morikawa; JP

- 12:30 - 12:30 49P - Computed tomographic features of pulmonary sarcomatoid carcinoma
M. Attia, K. Abdelmoula, H. Neji, M. Affes, S. Hantous-Zannad, A. Mekkaoui, I. Baccouche, K. Ben Miled-M'rad; TN
- 12:30 - 12:30 50P - Usefulness of F-18 FDG PET/CT to identify metastatic mediastinal lymph node in NSCLC patients with bilateral benign mediastinal lymph node hyperplasia
Y.S. Kim, S.H. Yoon, B.S. Son, D.H. Kim, K. Kim, S.-J. Kim; KR
- 12:30 - 12:30 SCLC
- 12:30 - 12:30 52P - Combined chemotherapy with etoposide, irinotecan plus cisplatin compared with topotecan monotherapy as the second-line treatment in sensitive relapsed small-cell lung cancer: a retrospective analysis
H. Wang, CN
- 12:30 - 12:30 53P - Systematic literature review of second- and third-line treatments used for small-cell lung cancer (SCLC)
R. Goulding¹, M. Lorenzi², Y. Yuan³, S. Bobiak³, N. Hertel³, B. Korytowsky³, J. Penrod³, J. Jansen^{2, 1}
BC/CA, ²CA/US, ³NJ/US
- 12:30 - 12:30 54P - Up Front Chemotherapy Dosing and Relative Dose Intensity in Extensive Stage Small Cell Lung Cancer
A. Mølby, B. Laursen, U. Falkmer, T. McCulloch, N. Jensen, L. Poulsen; DK
- 12:30 - 12:30 55P - Clinical Significance of EBUS-TBNA in patients with Small Cell Lung Cancer
Y.M. Lee, KR
- 12:30 - 12:30 56P - Pro-GRP in small cell lung cancer
S. Cavalieri, F. Nichetti, D. Morelli, F. de Braud, A. Martinetti, E. Sottotetti, K. Dotti, M. Prisciandaro, F. Corti, M. Platania; IT
- 12:30 - 12:30 57P - Small-Cell Lung Cancer: retrospective review of an institution
A. Silva, I. Guerreiro, C. Castro, M. Brandao, A. Rodrigues, C. Oliveira, I. Pousa, J. Oliveira, I. Azevedo, M. Soares; PT
- 12:30 - 12:30 58TiP - IMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC
M. Reck¹, A. Mansfield², S. Liu³, T.S.K. Mok⁴, X. Tang⁵, S. Lam⁶, F. Kabbinavar⁶, A. Lopez-Chavez⁶, A. Sandler⁶, L. Horn²; ¹DE, ²US, ³DC/US, ⁴CN, ⁵CH, ⁶CA/US
- 12:30 - 12:30 Early stage NSCLC
- 12:30 - 12:30 62P - Risk Factors Associated With Early vs Late Recurrence in Stage I Lung Adenocarcinoma



J. Qian¹, J. Xu², S. Wang², W. Yang², F. Qian², B. Zhang², R. Wang², X. Zhang², H. Wang², B. Han²;
¹US, ²CN

- 12:30 - 12:30 63P - Diabetes Predisposes Patients to Atrial Fibrillation after Robotic-Assisted Video-Thoroscopic Pulmonary Lobectomy
S. Reynolds, J. Glover, M. Echavarria, E. Ng, F. Velez-Cubian, C. Moodie, J. Garrett, J. Fontaine, E. Toloza; FL/US
- 12:30 - 12:30 64P - Smoking History as a Risk Factor for Atrial Fibrillation following Robotic-Assisted Video-Thoroscopic Pulmonary Lobectomy
J. Glover, S. Reynolds, M. Echavarria, E. Ng, F. Velez-Cubian, C. Moodie, J. Garrett, J. Fontaine, E. Toloza; FL/US
- 12:30 - 12:30 65P - Lymph node metastases in clinically node negative peripheral non small cell lung cancer
T. Mehmood, PK
- 12:30 - 12:30 66P - Effect of Age on Risk for Atrial Fibrillation following Robotic-Assisted Video-Thoroscopic Pulmonary Lobectomy
J. Glover, S. Reynolds, E. Ng, M. Echavarria, F. Velez-Cubian, C. Moodie, J. Garrett, J. Fontaine, E. Toloza; FL/US
- 12:30 - 12:30 67P - CT-guided fine-needle aspiration biopsy of pulmonary lesions under 15 mm of diameter: results on 68 consecutive patients
D. Tosi, A. Palleschi, L. Rosso, P. Mendogni, I. Righi, R. Carrinola, F. Damarco, M. Cattaneo, L. Santambrogio; IT
- 12:30 - 12:30 68P - Circulating Tumor Cells Spillage after Lung Nodule Biopsy
M. Sarfaty¹, N. Abdel-Rahman¹, A. Moore¹, J. Pfannkuche², C. Chudak², M. Kramer¹, N. Peled¹; ¹IL, ²DE
- 12:30 - 12:30 69P - CT-Guided Radiofrequency Ablation of Early Stage NSCLC
X. Zhang, CN
- 12:30 - 12:30 70P - A retrospective analysis to explore the value of gemcitabine combined with cisplatin as adjuvant chemotherapy of NSCLC.
D. Ma, J. Wang, X. Hao, Y. Wang, X. Hu, P. Xing, J. Li; CN
- 12:30 - 12:30 71TiP - A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC/ETOP 1416-PEARLS)
L. Paz-Ares¹, B. Hasan², U. Dafni³, J. Menis², E. De Maio², K. Oselin⁴, I. Albert⁵, M. Faehling⁶, P. Van Schil², M. O'Brien⁷; ¹ES, ²BE, ³GR, ⁴EE, ⁵HU, ⁶DE, ⁷GB
- 12:30 - 12:30 Locally advanced NSCLC
- 12:30 - 12:30 75P - Predictive value of CT texture analysis in lung cancer patients undergoing Nivolumab



V. Nardone, P. Tini, E. Aldi, P. Pastina, L. Sebaste, G. Battaglia, S.F. Carbone, V. Ricci, L. Pirtoli, P. Correale; IT

- 12:30 - 12:30 76P - Interpretation and Prognostic Value of PET-CT after Induction Chemotherapy with or without radiation in IIIA-N2 Non-Small Cell Lung Cancer Patients Who Receive Curative Surgery
J.H. Lee, KR
- 12:30 - 12:30 77P - Bronchoscopic Photodynamic Therapy for Treatment of Microscopic Residual disease post resection in Non-Small Cell Lung Cancer
A. Biswas, A. Khokar, S. Fernandez-Bussy, M. Jantz, H. Mehta; FL/US
- 12:30 - 12:30 78P - Comparison of chemoradiotherapy treatment strategies in Stage III non-small cell lung cancer among elderly patients from multiple data sources
H. Pang¹, T. Stinchcombe², P. Cheng¹, A. Lee¹, V. Lee¹, E. Vokes³, X. Wang²; ¹CN, ²NC/US, ³IL/US
- 12:30 - 12:30 79P - Long term survival of stage IIIb non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiation
T. Mehmood, PK
- 12:30 - 12:30 80TIP - A feasibility trial evaluating the addition of nivolumab to standard first-line chemo-radiotherapy in locally advanced stage IIIA/B NSCLC. The ETOP 6-14 NICOLAS trial.
S. Peters¹, R.A. Stahel¹, M. Kassapian², M. Guckenberger¹, E. Felip³, A.J. De Langen⁴, R. Huber⁵, H. Roschitzki-Voser¹, A.-C. Piguet¹, D. De Ruyscher⁴; ¹CH, ²GR, ³ES, ⁴NL, ⁵DE
- 12:30 - 12:30 Advanced NSCLC
- 12:30 - 12:30 97P - Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updates From the Pivotal Randomized Phase 2 Trial (ALTA)
M. Hochmair¹, M. Tiseo², K. Reckamp³, H. West⁴, H. Groen⁵, C. Langer⁶, W. Reichmann⁷, D. Kerstein⁷, D.-W. Kim⁸, D. Camidge⁹; ¹AT, ²IT, ³CA/US, ⁴WA/US, ⁵NL, ⁶PA/US, ⁷MA/US, ⁸KR, ⁹CO/US
- 12:30 - 12:30 98P - Retrospective indirect comparison of alectinib phase II data vs ceritinib real-world data in ALK+ NSCLC after progression on crizotinib
J. Davies¹, M. Martinec², R. Martina¹, P. Delmar², M. Coudert³, W. Bordogna², S. Golding², G. Crane¹; ¹GB, ²CH, ³FR
- 12:30 - 12:30 99P - Efficacy of gefitinib in advanced squamous cell lung cancer harboring epidermal growth factor receptor mutations: a pooled analysis of individual patient data
D. Tao, N. Zhang, Y. Wang; CN
- 12:30 - 12:30 100P - Afatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): analysis of time to treatment failure and impact of afatinib dose adjustment
J.C.-H. Yang¹, L. Paz-Ares², E.-H. Tan³, K. O'Byrne⁴, L. Zhang⁵, M. Boyer⁴, T. Mok⁵, V. Hirsh⁶, J. Fan⁷, K. Park⁸; ¹TW, ²ES, ³SG, ⁴NSW/AU, ⁵CN, ⁶QC/CA, ⁷CT/US, ⁸KR



- 12:30 - 12:30 101P - Association between time to progression and subsequent survival in previously treated BRAF V600E-mutant metastatic non-small cell lung cancer
M. Sasane¹, J. Li², J. Zhang³, J. Zhao², M.L. Ricculli⁴, S. Redhu¹, J. Signorovitch²; ¹NJ/US, ²MA/US, ³US, ⁴NY/US
- 12:30 - 12:30 102P - LUX-Lung 8 phase III trial: analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung
J.C.-H. Yang¹, G. Goss², E. Felip³, S. Lu⁴, A. Ardizzoni⁵, S. Gadgeel⁶, V. Georgoulas⁷, N. Dupuis⁸, E. Ehrnrooth⁹, J.-C. Soria¹⁰; ¹TW, ²ON/CA, ³ES, ⁴CN, ⁵IT, ⁶MI/US, ⁷GR, ⁸CO/US, ⁹DK, ¹⁰FR
- 12:30 - 12:30 103P - Re-biopsy for advanced non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy: CT characteristics of patients with T790M mutation and the use of various re-biopsy procedures
H.J. Koo, M.Y. Kim, C.-M. Choi, J.C. Lee, S. Park; KR
- 12:30 - 12:30 104P - Efficacy of ceritinib in a "real-world" population of crizotinib-refractory ALK-positive NSCLCs: results of the Italian compassionate use program
G. Metro, A. Passaro, G. Lo Russo, V. Gregorc, R. Giusti, E. Capelletto, O. Martelli, F. Cecere, L. Bonanno, R. Chiari; IT
- 12:30 - 12:30 105P - Prognostic Factors in Crizotinib (CRZ)-Resistant Anaplastic Lymphoma Kinase (ALK+) Non-Small Cell Lung Cancer (NSCLC) Patients (Pts)
K. Reckamp¹, J. Lee¹, J. Huang², I. Proskorovsky³, W. Reichmann², M. Krotneva³, D. Kerstein², H. Huang²; ¹CA/US, ²MA/US, ³QC/CA
- 12:30 - 12:30 106P - Brain metastases (BM) development in molecular selected non-small cell lung cancer (NSCLC) patients included in clinical trials
S. Cedres, N. Pardo, A. Navarro-Mendivil, A. Martinez, A. Martinez de Castro, J. Remon, F. Amair, J. Zeron, M. Vilaro, E. Felip; ES
- 12:30 - 12:30 107P - The real world experience of first generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in patients with advanced lung cancer; explorative analysis of big data from national health insurance service of Korea.
B.S. Kwon, J.C. Lee, S. Kim, M.Y. Kim, C.-M. Choi; KR
- 12:30 - 12:30 108P - NSCLC patients harbouring a rare or complex EGFR mutation are more often smokers and might not benefit from first line TKI therapy
D. Kauffmann-Guerrero, K. Kahnert, S. Reu, A. Jung, Z. Synyaeva, P. Mertsch, R. Huber; DE
- 12:30 - 12:30 109P - Sequential administration of EGFR-TKI and pemetrexed achieved a long period of response in advanced NSCLC patients with EGFR-mutant tumors
Y.-Y. Chen, Q.-Q. Zhu, L.-J. Dai, Z.-Y. Ding; CN
- 12:30 - 12:30 110P - Afatinib for patients with advanced NSCLC pretreated with chemotherapy and an EGFR tyrosine kinase inhibitor – Retrospective analysis of the Swiss Afatinib Named Patient Program
M. Ehmann, L. Wannesson, M. Pless, M. Früh, O. Gautschi, A. Curioni-Fontecedro, D. Betticher, M. Mark, A. Ochsenbein, S. Rothschild; CH
- 12:30 - 12:30 111P - Pharmacist Led Proactive Follow-up Algorithm for Advanced EGFR positive NSCLC Patients on Afatinib



P. Cheema¹, A. Thawer¹, J. Leake¹, S. Cheng¹, S. Khanna², J. Victor²; ¹CA, ²ON/CA

- 12:30 - 12:30 112P - Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade
S. Rothschild, C. Balmelli, L. Kaufmann, M. Stanczak, M. Syedbasha, D. Vogt, O. Gautschi, A. Egli, A. Zippelius, H. Laeubli; CH
- 12:30 - 12:30 113P - Clinical outcomes and quality of life (QoL) in adults with advanced refractory non-small cell lung cancer (NSCLC) patients receiving nivolumab (Nivo) as 2+ line treatment: interim analysis of expanded access program
K. Laktionov, L. Bolotina, V. Breder, A. Danilova, F. Moiseenko, T. Nikitina, R. Orlova, E. Filippova, S. Protsenko, T. Ionova; RU
- 12:30 - 12:30 114P - Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.
E.K. Cho, J.H. Kang, J.-Y. Han, J.S. Lee, D.-W. Kim, S.-W. Kim, Y.J. Min, K.H. Lee, J.-H. Kim, K. Park; KR
- 12:30 - 12:30 115P - Immune Related Adverse Events (irAE) and Disease Response with Nivolumab in pre-treated advanced Non Small Cell Lung Cancer (NSCLC)
E. Connolly¹, G. Mallesara², I. Nordman²; ¹AU, ²NSW/AU
- 12:30 - 12:30 116P - A randomized study to evaluate safety of DCVAC/LuCa added to chemotherapy with carboplatin and pemetrexed vs. chemotherapy alone in patients with stage IV non-small cell lung cancer
H. Zhong, R. Zhong, B. Yan; CN
- 12:30 - 12:30 117P - Symptomatic pneumonitis in the irradiated lung after nivolumab: Three case studies
O. Roengvoraphoj, C. Eze, M. Li, F. Manapov; DE
- 12:30 - 12:30 118P - Early onset of endocrine alterations during PD-L1 blockade in advanced NSCLC patients
C.E. Onesti, A. Botticelli, M. Occhipinti, F. Di Pietro, I. Zizzari, C. Napoletano, M. Nuti, S. Lauro, F. Mazzuca, P. Marchetti; IT
- 12:30 - 12:30 119P - A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): final results from squamous pts.
S. Thomas¹, R. Doebele², D. Spigel³, M. Tehfe⁴, M. Reck⁵, S. Verma⁴, A. Zimmermann⁶, E. Alexandris⁷, P. Lee⁷, P. Bonomi⁸; ¹CA/US, ²CO/US, ³TN/US, ⁴CA, ⁵DE, ⁶IN/US, ⁷NJ/US, ⁸IL/US
- 12:30 - 12:30 120P - Subgroup Analysis of Adenocarcinoma Patients Refractory to First-line Chemotherapy from REVEL, a Randomized Phase III Study of Docetaxel with Ramucirumab or Placebo for Second-line Treatment of Stage IV Non-small-cell Lung Cancer (NSCLC)
M. Reck¹, L. Paz-Ares², D. Moro-Sibilot³, F. Shepherd⁴, F. Cappuzzo⁵, K. Winfree⁶, E. Alexandris⁷, A. Sashegyi⁶, R. Varea⁶, M. Pérol³; ¹DE, ²ES, ³FR, ⁴CA, ⁵IT, ⁶IN/US, ⁷NJ/US
- 12:30 - 12:30 121P - Safety and efficacy of bevacizumab in "fragile" patients with advanced non-small cell lung cancer
C. Maragkos, D. Grapsa, G. Koumakis, A. Polyzos, K. Syrigos; GR



- 12:30 - 12:30 122P - Response to Metabolically Supported Chemotherapy (MSCT) with weekly Carboplatin/Paclitaxel in Advanced Stage /Metastatic (Stage IV) Non-Small Cell Lung Cancer: A Survival, Efficacy and Tolerability Analysis
M.S. Iyikesici, A. Slocum, A.K. Slocum, E. Turkmen, F.B. Berkarda; TR
- 12:30 - 12:30 123P - A retrospective study in Chinese patients: Is there a role of Nanoparticle Albumin Bound Paclitaxel in advanced NSCLC?
Y. Zhu, P. Xing, L. Shan, S. Chen, X. Hao, J. Li; CN
- 12:30 - 12:30 124P - Driverless lung carcinoma: Impact of expanded RNA and protein-based testing on detection of actionable biomarkers
Z. Gatalica¹, J. Xiu¹, W. Chen¹, T. Maney¹, A. Voss², N. Plowman³; ¹AZ/US, ²CH, ³GB
- 12:30 - 12:30 125P - Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): a prospective German Registry in stage IV NSCLC, AIO-TRK-0315
F. Griesinger, W. Eberhardt, N. Marschner, M. Jänicke, A. Fleitz, J. Sahlmann, A. Karatas, A. Hipper, M. Sebastian, M. Thomas; DE
- 12:30 - 12:30 126P - The Clinical Impact of Multiplex ctDNA Gene Analysis in Lung Cancer
S. Geva¹, T. Twito¹, A. Dvir¹, L. Soussan-Gutman¹, M. Ilouze¹, L. Roisman¹, E. Dudnik¹, A. Zer¹, R. Lanman², N. Peled¹; ¹IL, ²CA/US
- 12:30 - 12:30 127P - Prognostic Significance of Advanced Lung Cancer Inflammation Index (ALI) In Untreated and Treated Stage IV Non-Small Cell Lung Cancer (NSCLC): An Australian Cancer Centre Experience
H. Mandaliya¹, M. Jones¹, C. Oldmeadow², I. Nordman¹; ¹NSW/AU, ²AU
- 12:30 - 12:30 128P - serum DKK-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases
R. Qiao, T. Chu, B. Han, R. Zhong, Q. Chang, J. Teng, J. Pei; CN
- 12:30 - 12:30 129P - Procathepsin D as a novel diagnostic marker for malignant pleural effusion of lung cancer
C.Y. Lee, J.Y. Hong, M.-G. Lee, S.H. Jang; KR
- 12:30 - 12:30 130P - EGFR mutations in lung adenocarcinoma and brain metastases: a Croatian single institution experience.
K. Sreter, S. Kukulj, S. Smojver-Jezek, S. Seiwerth, M. Jakopovic, M. Samarzija; HR
- 12:30 - 12:30 131P - T790M co-exists with other secondary resistance mechanisms in EGFR mutation positive NSCLC and are associated with inferior outcomes
R. Teng, A. Takano, W.-L. Tan, M.-K. Ang, C.-K. Toh, Q.-S. Ng, W.-T. Lim, E.-H. Tan, T. Lim, D. Tan; SG
- 12:30 - 12:30 132P - Real world treatment patterns and outcomes for mNSCLC patients receiving second- and third-line therapy in Germany
N. Yu¹, I. Reyes-Rivera², J. Hipp³, M. Zou², N. Pillai², S. Hammerschmidt³; ¹GB, ²CH, ³DE
- 12:30 - 12:30 133P - The influence of body composition on TTFIELDS intensity in the lungs
U. Weinberg¹, N. Urman², H. Hershkovich², Z. Bomzon², E. Kirson², Y. Palti²; ¹CH, ²IL



- 12:30 - 12:30 134P - Applicable CT-guided percutaneous radiofrequency ablation RFA in the treatment of unresectable Lung Ground Glass Opacity GGO
Y. Wei, CN
- 12:30 - 12:30 135P - Coxsackievirus type B3 is a potent oncolytic virus against KRAS-mutant non-small-cell lung cancer
H. Deng, T. Sliva, Y. Xue, Y. Mohamud, J. Zhang, W. Lockwood, H. Luo; BC/CA
- 12:30 - 12:30 136P - Long-Term Safety and Efficacy of Darbepoetin alfa in Subjects With Stage IV NSCLC Receiving Multi-Cycle Chemotherapy
P. Gascón¹, R. Nagarkar², M. Šmakal³, K. Syrigos⁴, C. Barrios⁵, J. Cárdenas Sánchez⁶, L. Zhang⁷, D. Henry⁸, D. Tomita⁹, C. De Oliveira Brandao⁹; ¹ES, ²IN, ³CZ, ⁴GR, ⁵BR, ⁶MX, ⁷CN, ⁸PA/US, ⁹CA/US
- 12:30 - 12:30 137P - Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy
M. Pignata¹, K. Le Lay¹, L. Luciani¹, C. McConnachie², J. Gordon³, C. Chouaid¹, S. Roze¹; ¹FR, ²CH, ³DE
- 12:30 - 12:30 138TiP - An Open-label Phase 3b/4 Safety Trial of Flat-Dose Nivolumab Plus Ipilimumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
L. Paz-Ares¹, B. Lash², I. Albert³, G. Gagnon⁴, C. Chakmakjian⁵, N. Ready⁶, W. Hu⁷, L. Krug⁷, J. Fairchild⁷, R.N. Pillai⁸; ¹ES, ²PA/US, ³HU, ⁴QC/CA, ⁵TX/US, ⁶NC/US, ⁷NJ/US, ⁸GA/US
- 12:30 - 12:30 139TiP - A non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib according to the approved label (LUME-BioNIS)
M. Reck¹, A.J. Staal-Van den Brekel², A. Mellempgaard³, N. Morsli⁴, A.-M. Ellingboe⁵, R. Kaiser¹, K. Pietzko¹, T. Kitzing¹, J. Braunger¹, K. Kerr⁶; ¹DE, ²NL, ³DK, ⁴FR, ⁵NO, ⁶GB
- 12:30 - 12:30 140TiP - CheckMate 384: A Phase 3b/4 Dose-Frequency Optimization Trial of Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer
N. Reinmuth¹, R. Harris², P. Mitchell³, E.B. Garon⁴, J. Zhu⁵, I.-F. Chang⁵, E. Pichon⁶; ¹DE, ²NY/US, ³VIC/AU, ⁴CA/US, ⁵NJ/US, ⁶FR
- 12:30 - 12:30 141TiP - ASTRIS: A Multicenter, Real World Treatment Study of osimertinib in EGFR T790M Positive Non-Small Cell Lung Cancer (NSCLC)
P. Cheema¹, Y.-M. Chen², F. de Marinis³, H. Freitas⁴, S.-W. Kim⁵, A. Milner⁶, M. Provencio⁷, J. Rigas⁶, Y.-L. Wu⁸; ¹CA, ²TW, ³IT, ⁴BR, ⁵KR, ⁶GB, ⁷ES, ⁸CN
- 12:30 - 12:30 142TiP - A Prospective Multi-center Study to Investigate the EGFR-TKI Resistance Profile, Treatment Algorithm and Clinical Outcome in Chinese Patients with Advanced EGFRm+ NSCLC Who Have Received Prior First Generation EGFR TKI (PRECENT study, CCTC-1601, NCT02988141)
W. Liang, L. Wu, L. Wang, Y. Huang, R. Xu, L. Zhang, J. He; CN
- 12:30 - 12:30 143TiP - IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC



J. Jassem¹, F. de Marinis², D. Spigel³, S. Lam⁴, S. Mocchi⁴, A. Sandler⁴, A. Lopez-Chavez⁴, Y. Deng⁴, G. Giaccone⁵, R. Herbst⁶; ¹PL, ²IT, ³TN/US, ⁴CA/US, ⁵US, ⁶CT/US

12:30 - 12:30 144TiP - CheckMate 227: A Randomized, Open-label Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Nivolumab Plus Chemotherapy Versus Chemotherapy in Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

L. Paz-Ares¹, J. Brahmer², M.D. Hellmann³, M. Reck⁴, K. O'Byrne⁵, H. Borghaei⁶, W. Geese⁷, H. Lu⁷, F.E. Nathan⁷, S. Ramalingam⁸; ¹ES, ²MD/US, ³NY/US, ⁴DE, ⁵QLD/AU, ⁶PA/US, ⁷NJ/US, ⁸GA/US

12:30 - 12:30 145TiP - TTFIELDS combined with PD-1 inhibitors or docetaxel for 2nd Line Treatment of non-small-cell lung cancer (NSCLC): Phase 3 LUNAR study

U. Weinberg¹, O. Farber¹, M. Giladi², Z. Bomzon², E. Kirson²; ¹CH, ²IL

12:30 - 12:30 146TiP - eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

L. Horn¹, Y.-L. Wu², M. Reck³, C. Liang⁴, F. Tan², K. Harrow⁴, V. Oertel⁴, G. Dukart⁴, T.S.K. Mok²; ¹US, ²CN, ³DE, ⁴FL/US

12:30 - 12:30 Metastases to and from the lung

12:30 - 12:30 148P - Metastatic site location may influence the diagnostic accuracy of plasma EGFR-mutation testing in NSCLC: a pooled analysis

F. Passiglia¹, A. Listi¹, N. Barraco¹, A. Galvano¹, D. Fanale¹, L. Incorvaia¹, V. Bazan¹, C. Rolfo², A. Russo¹; ¹IT, ²BE

12:30 - 12:30 149P - PD-L1 expression patterns in the metastatic tumors to the lung: a comparative study with the primary non-small cell lung cancer

Z. Gatalica¹, J. Senarathne¹, S. Vranic²; ¹AZ/US, ²BA

12:30 - 12:30 150P - Immunohistochemical characteristics of brain metastases and corresponding primary lung cancer

D. Marinova, Y. Slavova, S. Nachev, D. Dimitrova, E. Mekov, M. Mihailov, D. Kostadinov, V. Youroukova; BG

12:30 - 12:30 151P - Predictors of Survival in Patients with Bone Metastasis of Lung Cancer

S. Jagadeesan, IN

12:30 - 12:30 152P - Relationship between overall survival and preoperative parameters in patients with colorectal cancer and synchronous liver and lung metastases

F. Lumachi, S. Basso, U. Zuccon, F. Maffei, A. Del Conte, P. Ubiali; IT

12:30 - 12:30 153P - Predictive markers of survival in patients with pulmonary metastases and malignant pleural effusion

F. Lumachi, S. Basso, R. Tozzoli, A. Del Conte, U. Zuccon, P. Ubiali; IT

12:30 - 12:30 154P - Analysis of factors affecting survival in patients with simultaneous liver and pulmonary metastases from colorectal cancer



F. Lumachi, S. Basso, U. Zuccon, F. Maffei, A. Del Conte, P. Ubiali; IT

- 12:30 - 12:30 155P - Combination of hepatic surgery and minimally invasive thoracic surgery using a subxyphoid approach through an abdominal incision.
M. Lim, D.H. Kim; KR
- 12:30 - 12:30 156P - Clinical outcome of Cyberknife radiosurgery in brain metastases of non-small cell lung cancer: a single institutional experience
S.-W. Lee, Y.-S. Kim, Y.K. Won, S.J. Lee, J.H. Hong, Y.N. Kang, J.H. Kang, S.-H. Hong, S.J. Kim, Y.K. Kim; KR
- 12:30 - 12:30 157P - Mediastinal masses: A study of our cases by transthoracic needle biopsy(TTNB) versus open surgery as a diagnostic procedure.
F. Gradica, L. Lisha, D. Argjiri, A. Cani, A. Leka, F. Kokici, S. Gradica, Y. Vata, F. Gradica, V. Rexha; AL
- 12:30 - 12:30 158TiP - Open Label, Multi-center, Prospective Study to Investigate the Efficacy and Safety of Osimertinib in Brain Metastases from Patients with EGFR T790M Positive NSCLC Who Have Received Prior Therapy with an EGFR-TKI (APOLLO Study, NCT02972333)
L. Wang, L. Xing, L. Cao, L. Wang, X. Wang, J. Feng, Y. Shu, Y. Shi, Y. Song, J. Yu; CN
- 12:30 - 12:30 159TiP - TTFIELDS and radiosurgery for 1-10 brain metastases from NSCLC: The Phase 3 METIS study
M. Mehta¹, V. Gondi², P. Brown³; ¹FL/US, ²IL/US, ³MN/US
- 12:30 - 12:30 Mesothelioma
- 12:30 - 12:30 160P - BAP1 in advanced sporadic malignant pleural mesothelioma
A. El Bastawisy, R. Shehab, A. Bahnassy, N. Sabri; EG
- 12:30 - 12:30 161P - Dkk1 stabilization as a new malignant pleural mesothelioma therapeutic avenue.
A. Guazzelli, E. Bakker, F. Sotgia, M. Listanti, M. Krstic-Demonacos, L. Mutti; GB
- 12:30 - 12:30 162P - Targeting the RON/MET/TAM signalling network in mesothelioma
A.-M. Baird¹, M. Jarzabek¹, L. Shiels¹, S. Raeppl², S. Finn¹, S. Cuffe¹, H. Pass³, I. Schmitt-Opitz⁴, A. Byrne¹, S. Gray¹; ¹IE, ²CA, ³US, ⁴CH
- 12:30 - 12:30 164P - Heart radiation dose as a risk factor for dyspnea worsening after multimodality treatment for Non-Small Cell Lung Cancer and Pleural Mesothelioma : an exploratory analysis
A. Botticella¹, C. Billiet¹, G. Defraene¹, C. Draulans¹, K. Nackaerts¹, C. Deroose¹, J. Coolen¹, P. Nafteux¹, D. De Ruysscher²; ¹BE, ²NL
- 12:30 - 12:30 165P - Malignant pleural mesothelioma: a systematic review of first-line chemotherapy and analysis of Hong Kong cohort
H. Pang, J. Ji, K. Yan, C.C. Leung, D. Lam; CN
- 12:30 - 12:30 166P - Thymoma and thymic carcinoma: a real-life retrospective analysis
I. Attili, S. Frega, A. Pavan, G. Pasello, V. Polo, G. Zago, F. Rea, F. Calabrese, P. Conte, L. Bonanno; IT



- 12:30 - 12:30 167P - Role of surgery in the treatment of thymic carcinoma based on a 5-year experience
F. Caushi, I. Skenduli, J. Shkurti, D. Xhemalaj, A. Hatibi, R. Kortoci, B. Gega, H. Hafizi; AL
- 12:30 - 12:30 168P - Clinical and prognostic characteristics of primary pulmonary non-Hodgkin's lymphoma: a retrospective analysis of 38 cases in a Chinese population
R. Qiao, B. Han, R. Zhong, Y. Zhao, T. Chu, L. Jiang, H. Zhong; CN
- 12:30 - 12:30 169P - Pulmonary carcinoid tumors: experience from an oncology center
L. Bei, A. Silva, A.L. Cunha, C. Franco, J. Oliveira, I. Azevedo, I. Pousa, A. Rodrigues, M. Soares, D. Pereira; PT
- 12:30 - 12:30 170TiP - LUME-Meso: Randomised Phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM)
S. Popat¹, R. Gaafar², A. Nowak³, A. Tsao⁴, J. Van Meerbeeck⁵, N. Vogelzang⁶, T. Nakano⁷, D. Velema⁸, N. Morsli⁹, G. Scagliotti¹⁰; ¹GB, ²EG, ³WA/AU, ⁴TX/US, ⁵BE, ⁶US, ⁷JP, ⁸ON/CA, ⁹FR, ¹⁰IT
- 13:00 - 14:00 Industry Satellite Symposium 3 Room A
- 14:10 - 14:40 Keynote lecture: Genetic profiling of lung cancer Room B
Chair: M. Reck, DE
- 14:10 - 14:40 Genetic profiling of lung cancer
M. Meyerson, US



14:45 - 16:15	Immunotherapies and targeted therapies in advanced NSCLC	Room B
14:45 - 14:57	<p>83O - A phase II study of Durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A</p> <p><u>V. Papadimitrakopoulou</u>¹, M. Redman², H. Borghaei³, S. Waqar⁴, F. Robert⁵, G. Kiefer³, S. McDonough², R. Herbst⁶, K. Kelly⁷, D. Gandara⁷; ¹TX/US, ²WA/US, ³PA/US, ⁴MO/US, ⁵AL/US, ⁶CT/US, ⁷CA/US</p>	
14:57 - 15:09	<p>84O - Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: efficacy data from the BIRCH trial</p> <p><u>S. Peters</u>¹, E. Carcereny Costa², M. Garassino³, D. Christoph⁴, T. Kurata⁵, J. Chait⁶, M. Johnson⁷, S. Mocchi⁸, S. Gettinger⁹, E. Felip²; ¹CH, ²ES, ³IT, ⁴DE, ⁵JP, ⁶NY/US, ⁷TN/US, ⁸CA/US, ⁹CT/US</p>	
15:09 - 15:21	<p>2O - Favorable clinical outcome and response to immunotherapy share a common PD-L1/PD-1 based NSCLC immune contexture</p> <p><u>G. Mazzaschi</u>, D. Madeddu, G. Bocchialini, L. Gnetti, G. Armani, F. Sogni, M. Tiseo, A. Ardizzoni, F. Aversa, F. Quaini; IT</p>	
15:21 - 15:36	Invited Discussant 83O, 84O and 2O	
15:36 - 15:48	<p>85O - Patient-reported symptoms and impact of treatment with osimertinib vs chemotherapy for advanced non-small-cell lung cancer</p> <p><u>C. Lee</u>¹, S. Novello², A. Ryden³, A. Templeton⁴, K. Rüdell⁴, H. Mann⁴, S. Giorghiu⁴, T. Mok⁵; ¹NSW/AU, ²IT, ³SE, ⁴GB, ⁵CN</p>	
15:48 - 16:00	One LBA TBC	
16:00 - 16:15	Invited Discussant 85O and one LBA TBC	



14:45 - 16:15	Liquid biopsies in NSCLC Chair: H. Wikman-Kocher, DE; N. Normanno, IT	Room A
14:45 - 15:00	Blood-based techniques for detecting tumour-derived biomarkers in lung cancer <u>N. Normanno</u> , IT	
15:00 - 15:15	Detection of CTCs in peripheral blood of lung cancer <u>H. Wikman-Kocher</u> , DE	
15:15 - 15:30	Circulating blood platelets: A novel liquid biopsy biosource <u>T. Würdinger</u> , NL	
15:30 - 15:45	Role of cfDNA to monitor EGFR dynamic changes and resistance in blood <u>T.S.K. Mok</u> , CN	
15:45 - 16:15	Panel discussion	



14:45 - 15:45	Imaging and locally advanced NSCLC Chair: S. Senan, NL; G. Rocco, IT; H. Prosch, AT	Room W
14:45 - 14:45	45PD - Mediastinal Nodal Staging of Non-Small Cell Lung Cancer Using Mediastinal Nodal Staging of Non-Small Cell Lung Cancer Using PET-CT in a Tuberculosis-Endemic Country <u>B. Khurse</u> , S. Kumar, S. Deo, P. Malik, V. Kumar, R. Kumar, D. Jain; IN	
14:45 - 14:45	46PD - The solid component evaluated on Computed tomography can predict the invasiveness and lymph node metastasis in lung adenocarcinoma as well as pathological invasive size <u>Y. Sakao</u> , H. Kuroda, T. Mizuno, N. Sakakura, Y. Yatabe; JP	
14:45 - 15:00	Invited Discussant 45PD and 46PD <u>H. Prosch</u> , AT	
15:00 - 15:05	Discussion	
15:05 - 15:05	61PD - Recurrence Risk-Scoring Model for Resected Stage I lung adenocarcinoma with solid component <u>J. Qian</u> ¹ , J. Xu ² , S. Wang ² , W. Yang ² , F. Qian ² , B. Zhang ² , R. Wang ² , X. Zhang ² , H. Wang ² , B. Han ² ; ¹ US, ² CN	
15:05 - 15:05	72PD - Video-Assisted Thoracic Surgery (VATS) Lobectomy for Non-Small Cell Lung Cancer After Induction Chemotherapy: A Propensity Score-Matched Analysis on Behalf of the Italian VATS Group <u>L. Bertolaccini</u> , A. Pardolesi, D. Argnani, J. Brandolini, D. Divisi, A. Bertani, A. Droghetti, A. Gonfiotti, R. Crisci, P. Solli; IT	
15:05 - 15:20	Invited Discussant 61PD and 72PD <u>G. Rocco</u> , IT	
15:20 - 15:25	Discussion	
15:25 - 15:25	73PD - Prognostic value of pre- to posttreatment primary tumor metabolic volume reduction on 18F-FDG-PET/CT in a patient cohort with inoperable locally-advanced NSCLC treated with definitive chemoradiotherapy <u>O. Roengvoraphoj</u> , C. Eze, W. Fendler, M. Dantes, C. Belka, F. Manapov; DE	
15:25 - 15:25	74PD - Radiation-induced lung toxicity prediction modeling in NSCLC: importance of baseline toxicity scoring <u>G. Defraene</u> ¹ , W. Van Elmpt ² , D. De Ruyscher ² ; ¹ BE, ² NL	
15:25 - 15:40	Invited Discussant 73PD and 74PD <u>S. Senan</u> , NL	
15:40 - 15:45	Discussion	



16:15 - 16:45	Coffee break	Hall 1
16:45 - 18:15	New molecular targets of interest beyond ALK and EGFR Chair: E. Smit, NL; D. Planchard, FR	Room B
16:45 - 17:05	Targeting RAS <u>E. Smit</u> , NL	
17:05 - 17:25	Targeting B-RAF <u>D. Planchard</u> , FR	
17:25 - 17:45	Targeting NTRK <u>F. de Braud</u> , IT	
17:45 - 18:05	Targeting MET <u>M. Awad</u> , US	
18:05 - 18:15	Questions and Answers	



16:45 - 18:15	Targeted therapies and management of brain metastasis	Room A
16:45 - 16:57	10 - ROS1 immunocytochemistry on cytological specimens in patients with non-small cell lung cancer <u>T. Vlajnic</u> , S. Savic, L. Bubendorf; CH	
16:57 - 17:09	86O - Afatinib (A) plus cetuximab (C) in the treatment of patients (pts) with NSCLC: the story so far <u>E. Smit</u> ¹ , J.-C. Soria ² , Y. Janjigian ³ , H. Groen ¹ , W. Pao ⁴ , E. Calvo ⁵ , A. Gazzah ² , J. Fan ⁶ , M. Ould-Kaci ⁶ , L. Horn ⁷ ; ¹ NL, ² FR, ³ NY/US, ⁴ TN/US, ⁵ ES, ⁶ CT/US, ⁷ US	
17:09 - 17:24	Invited Discussant 10 and 86O	
17:24 - 17:36	3O - Innate resistance in EGFR mutant non-small-cell lung cancer (NSCLC) patients by coactivation of receptor tyrosine kinases (RTKs) <u>R. Rosell</u> ¹ , N. Karachaliou ¹ , I. Chaib ¹ , A. Drozdowskyj ¹ , A. Frías ¹ , C. Teixidó ¹ , S. Viteri ¹ , L. Santarpia ² , M.A. Molina-Vila ¹ , T. Bivona ³ ; ¹ ES, ² IT, ³ US	
17:36 - 17:48	87O - Brigatinib in ALK+ NSCLC Pts With Intracranial CNS Metastases in 2 Clinical Trials <u>M. Tiseo</u> ¹ , R. Huber ² , M. Hochmair ³ , L. Bazhenova ⁴ , S.-H. Ou ⁴ , W. Reichmann ⁵ , J. Haney ⁵ , D. Kerstein ⁵ , D. Camidge ⁶ , S. Gettinger ⁷ ; ¹ IT, ² DE, ³ AT, ⁴ CA/US, ⁵ MA/US, ⁶ CO/US, ⁷ CT/US	
17:48 - 18:00	88O - CNS activity of ensartinib in ALK+ non-small cell lung cancer (NSCLC) patients (pts) <u>K. Reckamp</u> ¹ , S. Patel ¹ , G. Blumenschein ² , B. Gitlitz ¹ , S. Waqar ³ , G. Oxnard ⁴ , C. Brzezniak ⁵ , K. Harrow ⁶ , F. Tan ⁷ , L. Horn ⁸ ; ¹ CA/US, ² TX/US, ³ MO/US, ⁴ MA/US, ⁵ MD/US, ⁶ FL/US, ⁷ CN, ⁸ US	
18:00 - 18:15	Invited Discussant 3O, 87O and 88O	
18:40 - 19:40	Industry Satellite Symposium 4	Room A
18:40 - 19:40	Industry Satellite Symposium 5	Room C
07-05-2017		



08:00 - 08:50	Optimal management of stage III NSCLC in 2017 Chair: <u>A.D.L. Sihoe</u> , CN; S. Senan, NL	Room A
08:00 - 08:15	Surgical approach <u>A.D.L. Sihoe</u> , CN	
08:15 - 08:30	Radiotherapy approach <u>S. Senan</u> , NL	
08:30 - 08:50	Discussion	
08:00 - 08:50	Multiple lung nodules Chair: K. Suzuki, JP; F. Detterbeck, US	Room W
08:00 - 08:15	Staging: Diagnostic algorithms <u>F. Detterbeck</u> , US	
08:15 - 08:30	Therapeutic algorithms <u>K. Suzuki</u> , JP	
08:30 - 08:50	Discussion	
09:00 - 10:30	Management of NSCLC with resistance to first line targeted therapy Chair: D. Tan, SG; L. Horn, US	Room B
09:00 - 09:20	Management of T790M positive disease after EGFR TKI failure <u>C. Lovly</u> , US	
09:20 - 09:40	Management of T790M negative disease after EGFR TKI failure <u>M. Krebs</u> , GB	
09:40 - 10:00	Management of drug resistance in ALK positive NSCLC <u>D. Tan</u> , SG	
10:00 - 10:20	Management of resistance in other targets beyond ALK and EGFR <u>L. Friboulet</u> , FR	
10:20 - 10:30	Questions and Answers	



09:00 - 10:30	SCLC and early stage NSCLC	Room C
09:00 - 09:12	44O - Validation of the prognostic value of 8th edition revisions of the AJCC staging system for non small cell lung cancer; a SEER database analysis. <u>O. Abdel-Rahman</u> , EG	
09:12 - 09:24	59O - The impact of EGFR mutations on the prognosis of resected non-small cell lung cancer: A meta-analysis of literatures <u>W. Liang</u> , Q. He, W. Wang, J. He; CN	
09:24 - 09:36	60O - The benchmark of examined lymph node count in node positive NSCLC patients: A populational validation with SEER database <u>W. Liang</u> ¹ , J. He ¹ , G. Rocco ² , T. D'amico ³ , C.S.H. Ng ¹ , A. Brunelli ⁴ , C.-C. Liu ⁵ , R.H. Petersen ⁶ , J. He ¹ ; ¹ CN, ² IT, ³ NC/US, ⁴ GB, ⁵ TW, ⁶ DK	
09:36 - 09:51	Invited Discussant 44O, 59O and 60O <u>W. Eberhardt</u> , DE	
09:51 - 10:03	51O - Early limited-stage small-cell lung cancer: Sub-group analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial <u>A. Salem</u> ¹ , L. Ashcroft ¹ , A. Dagnault ² , C. de Metz ² , M. Hatton ¹ , I. Locke ¹ , I. Monnet ³ , L. Padovani ³ , F. Blackhall ¹ , C. Faivre-Finn ¹ ; ¹ GB, ² CA, ³ FR	
10:03 - 10:15	One LBA TBC	
10:15 - 10:30	Invited Discussant 51O and one LBA TBC <u>S. Popat</u> , GB	
09:15 - 10:15	Is there a role for second-line immunotherapy in patients with PD-L1 negative NSCLC? Chair: M. Reck, DE; L. Paz-Ares, ES	Room A
09:15 - 09:25	Introduction and first vote	
09:25 - 09:45	Yes <u>R. Herbst</u> , US	
09:45 - 10:05	No <u>B. Besse</u> , FR	
10:05 - 10:15	Second vote and conclusions	



10:30 - 11:00 Coffee break Hall 1

11:00 - 12:30 Molecular understanding of lung cancer: The role of the host and environment Room B
Chair: D. Carbone, US; M. Meyerson, US

11:00 - 11:20 Role of the microbiome in lung cancer
B. Cookson, GB

11:20 - 11:40 Tumour clonal symbiosis
M. Janiszewska, US

11:40 - 12:00 Homotypic and heterotypic interactions in lung carcinogenesis
L.M. Montuenga, ES

12:00 - 12:20 Tumour mutations that alter antigen presentation/signalling
M. Meyerson, US

12:20 - 12:30 Questions and Answers

11:00 - 12:30 What should non-Surgeons expect from Surgeons? Room A
Chair: D. Waller, GB; R.A. Stahel, CH

11:00 - 11:20 Minimal requirements for surgical participation in CT screening programmes
J.H. Pedersen, DK

11:20 - 11:40 Surgeon-led randomised trials: The case of mesothelioma
J. Edwards, GB

11:40 - 12:00 The approach of Surgeons towards N2 NSCLC
G. Massard, FR

12:00 - 12:20 The impact of international surgical registries on multidisciplinary decisions: The case of thymic tumours and NET
P.L. Filosso, IT

12:20 - 12:30 Questions and Answers



11:00 - 12:30	SCLC: New insights Chair: N. Reguart, ES; C. Dive, GB	Room C
11:00 - 11:20	What is the optimal thoracic radiotherapy in limited stage SCLC? <u>C. Faivre-Finn</u> , GB	
11:20 - 11:40	Can brain control be improved beyond PCI? <u>A. Grosu</u> , DE	
11:40 - 12:00	New therapies, new era? <u>N. Reguart</u> , ES	
12:00 - 12:20	What can CDX models teach us? <u>C. Dive</u> , GB	
12:20 - 12:30	Questions and Answers	
12:30 - 13:00	Poster Display Session	Hall 1
12:30 - 12:30	Tumour biology and pathology	
12:30 - 12:30	4P - PD-L1 in NSCLC cytology <u>M. Kovacevic</u> , I. Kern, S. Gabrič; SI	
12:30 - 12:30	5P - Repeated biopsy for mutational analysis on EGFR-mutated non-small cell lung cancer (EGFR-NSCLC): feasibility and safety <u>G. Anguera</u> , M. Riudavets, A. Torrego, V. Pajares, A. Gimenez, L. López-Vilaró, E. Martínez, J.C. Trujillo-Reyes, E. Lerma, M. Majem; ES	
12:30 - 12:30	6P - Metformin sensitizes lung cancer cells to treatment by the Tyrosine Kinase Inhibitor erlotinib <u>X. Wang</u> , Y. Xiang, B. Gao; CN	
12:30 - 12:30	7P - Population-level effect of targeted therapy in patients with advanced pulmonary adenocarcinoma: a Swiss prospective cohort study <u>C. Schwegler</u> , D. Kaufmann, O. Gautschi, S. Aebi, J. Diebold, D. Pfeiffer; CH	
12:30 - 12:30	8P - Expression of genes associated with anti-viral response in EGFR mutant non-small-cell lung cancer (NSCLC). <u>N. Karachaliou</u> ¹ , A. Giménez-Capitán ¹ , A. Drozdowskyj ¹ , E. Aldeguer ¹ , M. González Cao ¹ , A.F. Cardona ² , G. López-Vivanco ¹ , J.M. Sánchez ¹ , M. Gil ¹ , R. Rosell ¹ ; ¹ ES, ² CO	
12:30 - 12:30	9P - Knockdown of MFN2 gene expression inhibits lung adenocarcinoma cell proliferation <u>Y. Lou</u> , Y. Zhang, J. Xu, P. Gu, W. Zhang, X. Zhang, H. Zhong, L. Jiang, B. Han; CN	



- 12:30 - 12:30 10P - In Vivo Evaluation of Combretastatin A-4 Phosphate for lung cancer by Bioluminescence Imaging and Multispectral Optoacoustic Tomography
L. Liu, S. Kumari, J. Campbell, R. Mason, L. Zhang; TX/US
- 12:30 - 12:30 11P - Prognostic significance of different immunohistochemical markers in small cell lung cancer
E. Gkika, S. Beitinger, S. Adebahr, T. Schimek-Jasch, S. Wiesemann, C. Waller, A. Grosu, U. Nestle, G. Kayser; DE
- 12:30 - 12:30 12P - Thyroid transcription factor-1 as a prognosticator in patients with metastatic lung adenocarcinoma without EGFR sensitizing mutations
J.Y. Park, S.H. Jang, J.-H. Kim, S. Park, Y.I. Hwang, K.-S. Jung, J.W. Seo; KR
- 12:30 - 12:30 13P - Characterizing the DNA damage response in putative stem cells of resected normal lung and matched NSCLC patient samples
T. Marti, C. Tièche, R. Peng, S. Hall, L. Froment, P. Dorn, S. Berezowska, R. Schmid; CH
- 12:30 - 12:30 14P - Histone H2AX phosphorylation increases apoptosis of lung cancer cells by miR-3196/PUMA pathway
C. Lu, C. Xu, L. Zhang, L. Duan; CN
- 12:30 - 12:30 15P - PLGF regulates crosstalk between non-small cell lung cancer cells and tumor-associated macrophages in cancer vascularization and growth
W. Zhang, Y. Lou, B. Yan, Y. Zhao, S. Cui, L. Jiang, B. Han; CN
- 12:30 - 12:30 16P - Carvacrol induces growth inhibition and circumvents chemoresistance via inhibition of STAT3/Skp2/p27 pathway in non-small lung cancer cells.
K.-C. Kim, C. Lee; KR
- 12:30 - 12:30 Prevention, Early detection, Epidemiology, Tobacco control
- 12:30 - 12:30 19P - Domestic Cooking Fuel as a Risk Factor for Lung Cancer in Women - A Case control study
S. Katpattil, IN
- 12:30 - 12:30 21P - The efficacy of combination therapy with Varenicline and Bupropion for smoking cessation.
D. Johns, IN
- 12:30 - 12:30 23P - Pictorial warning on cigarette packets and its role in tobacco cessation- questionnaire survey among cigarette smokers in Chennai.
C.J.K. Francis, IN
- 12:30 - 12:30 25P - Tobacco Consumption Pattern among Auto Rickshaw Drivers in Chennai City, Tamil Nadu, India
D.L. Francis, IN
- 12:30 - 12:30 26P - Smoking habits and awareness about anti-smoking acts among General Public in Gurgaon, Haryana, India.
C.J.K. Francis, IN



- 12:30 - 12:30 27P - Factors causing treatment delays and its impact on treatment outcome in patients of lung cancer-an analysis.
D. Kumar, S. Singh; IN
- 12:30 - 12:30 28P - Impact of a pharmaceutical consultation, review of a pilot study
E. Clou, J. Gaudas, K. Ahmed, D. Avenin, A. Estes, G. Galula, J. Fillon, J.P. Lotz, I. Debrix; FR
- 12:30 - 12:30 29P - Baseline Characteristics of Participants in PL-208: A Multi-Center Trial of the ProLung Test™ (Transthoracic Bioconductance Measurement) as an Adjunct to CT Chest Scans for the Risk Stratification of Patients with Pulmonary Lesions Suspicious for Lung Cancer
R. Yung¹, D. Ost², M. Simoff³, C. Reddy⁴, A. Goyal⁵, I. Barjakarevic⁶, M. Garff⁴, K. Larson⁴, J. O'Driscoll⁴, S. Makani⁶; ¹MD/US, ²TX/US, ³MI/US, ⁴UT/US, ⁵IL/US, ⁶CA/US
- 12:30 - 12:30 Translational research
- 12:30 - 12:30 31P - Targeted therapy for patients with ALK positive NSCLC: results from the transalpine cohort
C. Britschgi¹, M. Rechsteiner¹, R. Delaloye¹, M. Früh¹, G. Metro², O. Gautschi¹, S. Rothschild¹, R. Stahel¹, P. Wild¹, A. Curioni-Fontecedro¹; ¹CH, ²IT
- 12:30 - 12:30 32P - Effects of BTK inhibitor on gefitinib-resistance non-small cell lung cancer
T.-M. Hong, Y.-T. Fang, Y.-L. Chen; TW
- 12:30 - 12:30 33P - The screening and characterization of aptamer against gefitinib resistant cells
Y.-L. Chen, J.-E. Wu, T.-M. Hong; TW
- 12:30 - 12:30 34P - Discovery of 1,3,5-triazine-monastrol based novel EGFR-tyrosine kinase inhibitor against human lung carcinoma
U. Singh, J. Shrivastava, A. Verma, H. Bhat; IN
- 12:30 - 12:30 35P - CDK7 inhibition as a promising therapeutic strategy in lung squamous cell carcinoma with SOX2 amplification
J.C. Lee, J.Y. Hur, J.K. Rho, H.R. Kim, C.-M. Choi; KR
- 12:30 - 12:30 36P - Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab
F. Passiglia, A. Perez, A. Listi, M. Castiglia, E. Musso, C. Ancona, S. Rizzo, M. Alù, L. Blasi, A. Russo; IT
- 12:30 - 12:30 37P - Can we perform subtyping of non-small cell lung cancer patients by use of lung tissue metabolic fingerprinting?
M. Ciborowski, J. Kisluk, K. Pietrowska, P. Samczuk, E. Parfieniuk, T. Kowalczyk, M. Kozłowski, A. Kretowski, J. Niklinski; PL
- 12:30 - 12:30 38P - Flow cytometry immunophenotyping of pleural fluid cytology in patients with diffuse large B-cell lymphoma (DLBCL) and malignant pleural effusion
F. Lumachi, P. Ubiali, R. Tozzoli, S. Sulfaro, S. Basso; IT
- 12:30 - 12:30 39P - Efficacy of Tumor Treating Fields (TTFields) and anti-PD-1 in non-small-cell lung cancer (NSCLC) preclinical models



U. Weinberg¹, T. Voloshin², O. Yitzaki², N. Kaynan², M. Giladi², A. Shteingauz², M. Munster², S. Cahal², E. Kirson², Y. Palti²; ¹CH, ²IL

- 12:30 - 12:30 40P - Antitumoral effect and reduced systemic toxicity in mice after intra-tumoral injection of an in vivo solidifying calcium sulfate formulation with docetaxel
M. Sandelin, S. Grudén, V. Rasanen, P. Micke, M. Hedeland, N. Axén, M. Jeansson; SE
- 12:30 - 12:30 41P - Development of novel 1,2,4--triazole--thiol derivatives as dual PI3K/mTOR inhibitor against the non-small cell lung cancer (NSCLC)
A. Verma, V. Kumar, U. Singh; IN
- 12:30 - 12:30 42P - Dual inhibitory effects of novel Naringenin analogue in tobacco-carcinogen induced lung cancer via inhibition of PI3K/Akt/mTOR pathway
V. Kumar, A. Verma, P. Bhatt; IN
- 12:30 - 12:30 43P - A phase I-II clinical trial to evaluate the safety, pharmacokinetics and efficacy of high dose intravenous ascorbic acid synergy with mEHT in Chinese patients with stage III-IV Non-Small Cell Lung Cancer
J. Ou, X. Zhu, Y. Lu, C. Zhao, H. Zhang, X. Gui, X. Wang, X. Zhang, T. Zhang, C.L.K. Pang; CN
- 12:30 - 12:30 Imaging and staging
- 12:30 - 12:30 47P - Multi Detector CT evaluation of suspicious malignant lung masses with its Combined wash-in & wash-out features and their histopathological correlation
S. Khanduri, S. Bhagat; IN
- 12:30 - 12:30 48P - Evaluation of Neoplasms Incidentally Detected by Preoperative FDG-PET/CT for Primary Lung Cancer.
Y. Noda, H. Matsudaira, S. Arakawa, K. Yoshida, T. Morikawa; JP
- 12:30 - 12:30 49P - Computed tomographic features of pulmonary sarcomatoid carcinoma
M. Attia, K. Abdelmoula, H. Neji, M. Affes, S. Hantous-Zannad, A. Mekkaoui, I. Baccouche, K. Ben Miled-M'rad; TN
- 12:30 - 12:30 50P - Usefulness of F-18 FDG PET/CT to identify metastatic mediastinal lymph node in NSCLC patients with bilateral benign mediastinal lymph node hyperplasia
Y.S. Kim, S.H. Yoon, B.S. Son, D.H. Kim, K. Kim, S.-J. Kim; KR
- 12:30 - 12:30 SCLC
- 12:30 - 12:30 52P - Combined chemotherapy with etoposide, irinotecan plus cisplatin compared with topotecan monotherapy as the second-line treatment in sensitive relapsed small-cell lung cancer: a retrospective analysis
H. Wang, CN
- 12:30 - 12:30 53P - Systematic literature review of second- and third-line treatments used for small-cell lung cancer (SCLC)



R. Goulding¹, M. Lorenzi², Y. Yuan³, S. Bobiak³, N. Hertel³, B. Korytowsky³, J. Penrod³, J. Jansen²; ¹BC/CA, ²CA/US, ³NJ/US

- 12:30 - 12:30 54P - Up Front Chemotherapy Dosing and Relative Dose Intensity in Extensive Stage Small Cell Lung Cancer
A. Mølby, B. Laursen, U. Falkmer, T. McCulloch, N. Jensen, L. Poulsen; DK
- 12:30 - 12:30 55P - Clinical Significance of EBUS-TBNA in patients with Small Cell Lung Cancer
Y.M. Lee, KR
- 12:30 - 12:30 56P - Pro-GRP in small cell lung cancer
S. Cavaliere, F. Nichetti, D. Morelli, F. de Braud, A. Martinetti, E. Sottotetti, K. Dotti, M. Prisciandaro, F. Corti, M. Platania; IT
- 12:30 - 12:30 57P - Small-Cell Lung Cancer: retrospective review of an institution
A. Silva, I. Guerreiro, C. Castro, M. Brandao, A. Rodrigues, C. Oliveira, I. Pousa, J. Oliveira, I. Azevedo, M. Soares; PT
- 12:30 - 12:30 58TiP - IMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC
M. Reck¹, A. Mansfield², S. Liu³, T.S.K. Mok⁴, X. Tang⁵, S. Lam⁶, F. Kabbinavar⁶, A. Lopez-Chavez⁶, A. Sandler⁶, L. Horn²; ¹DE, ²US, ³DC/US, ⁴CN, ⁵CH, ⁶CA/US
- 12:30 - 12:30 Early stage NSCLC
- 12:30 - 12:30 62P - Risk Factors Associated With Early vs Late Recurrence in Stage I Lung Adenocarcinoma
J. Qian¹, J. Xu², S. Wang², W. Yang², F. Qian², B. Zhang², R. Wang², X. Zhang², H. Wang², B. Han²; ¹US, ²CN
- 12:30 - 12:30 63P - Diabetes Predisposes Patients to Atrial Fibrillation after Robotic-Assisted Video-Thoroscopic Pulmonary Lobectomy
S. Reynolds, J. Glover, M. Echavarria, E. Ng, F. Velez-Cubian, C. Moodie, J. Garrett, J. Fontaine, E. Toloza; FL/US
- 12:30 - 12:30 64P - Smoking History as a Risk Factor for Atrial Fibrillation following Robotic-Assisted Video-Thoroscopic Pulmonary Lobectomy
J. Glover, S. Reynolds, M. Echavarria, E. Ng, F. Velez-Cubian, C. Moodie, J. Garrett, J. Fontaine, E. Toloza; FL/US
- 12:30 - 12:30 65P - Lymph node metastases in clinically node negative peripheral non small cell lung cancer
T. Mehmood, PK
- 12:30 - 12:30 66P - Effect of Age on Risk for Atrial Fibrillation following Robotic-Assisted Video-Thoroscopic Pulmonary Lobectomy
J. Glover, S. Reynolds, E. Ng, M. Echavarria, F. Velez-Cubian, C. Moodie, J. Garrett, J. Fontaine, E. Toloza; FL/US



- 12:30 - 12:30 67P - CT-guided fine-needle aspiration biopsy of pulmonary lesions under 15 mm of diameter: results on 68 consecutive patients
D. Tosi, A. Palleschi, L. Rosso, P. Mendogni, I. Righi, R. Carrinola, F. Damarco, M. Cattaneo, L. Santambrogio; IT
- 12:30 - 12:30 68P - Circulating Tumor Cells Spillage after Lung Nodule Biopsy
M. Sarfaty¹, N. Abdel-Rahman¹, A. Moore¹, J. Pfannkuche², C. Chudak², M. Kramer¹, N. Peled¹; ¹IL, ²DE
- 12:30 - 12:30 69P - CT-Guided Radiofrequency Ablation of Early Stage NSCLC
X. Zhang, CN
- 12:30 - 12:30 70P - A retrospective analysis to explore the value of gemcitabine combined with cisplatin as adjuvant chemotherapy of NSCLC.
D. Ma, J. Wang, X. Hao, Y. Wang, X. Hu, P. Xing, J. Li; CN
- 12:30 - 12:30 71TiP - A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC/ETOP 1416-PEARLS)
L. Paz-Ares¹, B. Hasan², U. Dafni³, J. Menis², E. De Maio², K. Oselin⁴, I. Albert⁵, M. Faehling⁶, P. Van Schil², M. O'Brien⁷; ¹ES, ²BE, ³GR, ⁴EE, ⁵HU, ⁶DE, ⁷GB
- 12:30 - 12:30 Locally advanced NSCLC
- 12:30 - 12:30 75P - Predictive value of CT texture analysis in lung cancer patients undergoing Nivolumab
V. Nardone, P. Tini, E. Aldi, P. Pastina, L. Sebaste, G. Battaglia, S.F. Carbone, V. Ricci, L. Pirtoli, P. Correale; IT
- 12:30 - 12:30 76P - Interpretation and Prognostic Value of PET-CT after Induction Chemotherapy with or without radiation in IIIA-N2 Non-Small Cell Lung Cancer Patients Who Receive Curative Surgery
J.H. Lee, KR
- 12:30 - 12:30 77P - Bronchoscopic Photodynamic Therapy for Treatment of Microscopic Residual disease post resection in Non-Small Cell Lung Cancer
A. Biswas, A. Khokar, S. Fernandez-Bussy, M. Jantz, H. Mehta; FL/US
- 12:30 - 12:30 78P - Comparison of chemoradiotherapy treatment strategies in Stage III non-small cell lung cancer among elderly patients from multiple data sources
H. Pang¹, T. Stinchcombe², P. Cheng¹, A. Lee¹, V. Lee¹, E. Vokes³, X. Wang²; ¹CN, ²NC/US, ³IL/US
- 12:30 - 12:30 79P - Long term survival of stage IIIb non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiation
T. Mehmood, PK
- 12:30 - 12:30 80TiP - A feasibility trial evaluating the addition of nivolumab to standard first-line chemo-radiotherapy in locally advanced stage IIIA/B NSCLC. The ETOP 6-14 NICOLAS trial.



S. Peters¹, R.A. Stahel¹, M. Kassapian², M. Guckenberger¹, E. Felip³, A.J. De Langen⁴, R. Huber⁵, H. Roschitzki-Voser¹, A.-C. Piguet¹, D. De Ruyscher⁴; ¹CH, ²GR, ³ES, ⁴NL, ⁵DE

12:30 - 12:30 Advanced NSCLC

12:30 - 12:30 97P - Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updates From the Pivotal Randomized Phase 2 Trial (ALTA)

M. Hochmair¹, M. Tiseo², K. Reckamp³, H. West⁴, H. Groen⁵, C. Langer⁶, W. Reichmann⁷, D. Kerstein⁷, D.-W. Kim⁸, D. Camidge⁹; ¹AT, ²IT, ³CA/US, ⁴WA/US, ⁵NL, ⁶PA/US, ⁷MA/US, ⁸KR, ⁹CO/US

12:30 - 12:30 98P - Retrospective indirect comparison of alectinib phase II data vs ceritinib real-world data in ALK+ NSCLC after progression on crizotinib

J. Davies¹, M. Martinec², R. Martina¹, P. Delmar², M. Coudert³, W. Bordogna², S. Golding², G. Crane¹; ¹GB, ²CH, ³FR

12:30 - 12:30 99P - Efficacy of gefitinib in advanced squamous cell lung cancer harboring epidermal growth factor receptor mutations: a pooled analysis of individual patient data

D. Tao, N. Zhang, Y. Wang; CN

12:30 - 12:30 100P - Afatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): analysis of time to treatment failure and impact of afatinib dose adjustment

J.C.-H. Yang¹, L. Paz-Ares², E.-H. Tan³, K. O'Byrne⁴, L. Zhang⁵, M. Boyer⁴, T. Mok⁵, V. Hirsh⁶, J. Fan⁷, K. Park⁸; ¹TW, ²ES, ³SG, ⁴NSW/AU, ⁵CN, ⁶QC/CA, ⁷CT/US, ⁸KR

12:30 - 12:30 101P - Association between time to progression and subsequent survival in previously treated BRAF V600E-mutant metastatic non-small cell lung cancer

M. Sasane¹, J. Li², J. Zhang³, J. Zhao², M.L. Ricculli⁴, S. Redhu¹, J. Signorovitch²; ¹NJ/US, ²MA/US, ³US, ⁴NY/US

12:30 - 12:30 102P - LUX-Lung 8 phase III trial: analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung

J.C.-H. Yang¹, G. Goss², E. Felip³, S. Lu⁴, A. Ardizzoni⁵, S. Gadgeel⁶, V. Georgoulas⁷, N. Dupuis⁸, E. Ehrnrooth⁹, J.-C. Soria¹⁰; ¹TW, ²ON/CA, ³ES, ⁴CN, ⁵IT, ⁶MI/US, ⁷GR, ⁸CO/US, ⁹DK, ¹⁰FR

12:30 - 12:30 103P - Re-biopsy for advanced non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy: CT characteristics of patients with T790M mutation and the use of various re-biopsy procedures

H.J. Koo, M.Y. Kim, C.-M. Choi, J.C. Lee, S. Park; KR

12:30 - 12:30 104P - Efficacy of ceritinib in a "real-world" population of crizotinib-refractory ALK-positive NSCLCs: results of the Italian compassionate use program

G. Metro, A. Passaro, G. Lo Russo, V. Gregorc, R. Giusti, E. Capelletto, O. Martelli, F. Cecere, L. Bonanno, R. Chiari; IT

12:30 - 12:30 105P - Prognostic Factors in Crizotinib (CRZ)-Resistant Anaplastic Lymphoma Kinase (ALK+) Non-Small Cell Lung Cancer (NSCLC) Patients (Pts)



K. Reckamp¹, J. Lee¹, J. Huang², I. Proskorovsky³, W. Reichmann², M. Krotneva³, D. Kerstein², H. Huang²; ¹CA/US, ²MA/US, ³QC/CA

- 12:30 - 12:30 106P - Brain metastases (BM) development in molecular selected non-small cell lung cancer (NSCLC) patients included in clinical trials
S. Cedres, N. Pardo, A. Navarro-Mendivil, A. Martinez, A. Martinez de Castro, J. Remon, F. Amair, J. Zeron, M. Vilaro, E. Felip; ES
- 12:30 - 12:30 107P - The real world experience of first generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in patients with advanced lung cancer; explorative analysis of big data from national health insurance service of Korea.
B.S. Kwon, J.C. Lee, S. Kim, M.Y. Kim, C.-M. Choi; KR
- 12:30 - 12:30 108P - NSCLC patients harbouring a rare or complex EGFR mutation are more often smokers and might not benefit from first line TKI therapy
D. Kauffmann-Guerrero, K. Kahnert, S. Reu, A. Jung, Z. Synyaeva, P. Mertsch, R. Huber; DE
- 12:30 - 12:30 109P - Sequential administration of EGFR-TKI and pemetrexed achieved a long period of response in advanced NSCLC patients with EGFR-mutant tumors
Y.-Y. Chen, Q.-Q. Zhu, L.-J. Dai, Z.-Y. Ding; CN
- 12:30 - 12:30 110P - Afatinib for patients with advanced NSCLC pretreated with chemotherapy and an EGFR tyrosine kinase inhibitor – Retrospective analysis of the Swiss Afatinib Named Patient Program
M. Ehmann, L. Wannesson, M. Pless, M. Früh, O. Gautschi, A. Curioni-Fontecedro, D. Betticher, M. Mark, A. Ochsenbein, S. Rothschild; CH
- 12:30 - 12:30 111P - Pharmacist Led Proactive Follow-up Algorithm for Advanced EGFR positive NSCLC Patients on Afatinib
P. Cheema¹, A. Thawer¹, J. Leake¹, S. Cheng¹, S. Khanna², J. Victor²; ¹CA, ²ON/CA
- 12:30 - 12:30 112P - Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade
S. Rothschild, C. Balmelli, L. Kaufmann, M. Stanczak, M. Syedbasha, D. Vogt, O. Gautschi, A. Egli, A. Zippelius, H. Laeubli; CH
- 12:30 - 12:30 113P - Clinical outcomes and quality of life (QoL) in adults with advanced refractory non-small cell lung cancer (NSCLC) patients receiving nivolumab (Nivo) as 2+ line treatment: interim analysis of expanded access program
K. Laktionov, L. Bolotina, V. Breder, A. Danilova, F. Moiseenko, T. Nikitina, R. Orlova, E. Filippova, S. Protsenko, T. Ionova; RU
- 12:30 - 12:30 114P - Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.
E.K. Cho, J.H. Kang, J.-Y. Han, J.S. Lee, D.-W. Kim, S.-W. Kim, Y.J. Min, K.H. Lee, J.-H. Kim, K. Park; KR
- 12:30 - 12:30 115P - Immune Related Adverse Events (irAE) and Disease Response with Nivolumab in pre-treated advanced Non Small Cell Lung Cancer (NSCLC)
E. Connolly¹, G. Mallesara², I. Nordman²; ¹AU, ²NSW/AU



- 12:30 - 12:30 116P - A randomized study to evaluate safety of DCVAC/LuCa added to chemotherapy with carboplatin and pemetrexed vs. chemotherapy alone in patients with stage IV non-small cell lung cancer
H. Zhong, R. Zhong, B. Yan; CN
- 12:30 - 12:30 117P - Symptomatic pneumonitis in the irradiated lung after nivolumab: Three case studies
O. Roengvoraphoj, C. Eze, M. Li, F. Manapov; DE
- 12:30 - 12:30 118P - Early onset of endocrine alterations during PD-L1 blockade in advanced NSCLC patients
C.E. Onesti, A. Botticelli, M. Occhipinti, F. Di Pietro, I. Zizzari, C. Napoletano, M. Nuti, S. Lauro, F. Mazzuca, P. Marchetti; IT
- 12:30 - 12:30 119P - A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): final results from squamous pts.
S. Thomas¹, R. Doebele², D. Spigel³, M. Tehfe⁴, M. Reck⁵, S. Verma⁴, A. Zimmermann⁶, E. Alexandris⁷, P. Lee⁷, P. Bonomi⁸; ¹CA/US, ²CO/US, ³TN/US, ⁴CA, ⁵DE, ⁶IN/US, ⁷NJ/US, ⁸IL/US
- 12:30 - 12:30 120P - Subgroup Analysis of Adenocarcinoma Patients Refractory to First-line Chemotherapy from REVEL, a Randomized Phase III Study of Docetaxel with Ramucirumab or Placebo for Second-line Treatment of Stage IV Non-small-cell Lung Cancer (NSCLC)
M. Reck¹, L. Paz-Ares², D. Moro-Sibilot³, F. Shepherd⁴, F. Cappuzzo⁵, K. Winfree⁶, E. Alexandris⁷, A. Sashegyi⁶, R. Varea⁶, M. Pérol³; ¹DE, ²ES, ³FR, ⁴CA, ⁵IT, ⁶IN/US, ⁷NJ/US
- 12:30 - 12:30 121P - Safety and efficacy of bevacizumab in "fragile" patients with advanced non-small cell lung cancer
C. Maragkos, D. Grapsa, G. Koumakis, A. Polyzos, K. Syrigos; GR
- 12:30 - 12:30 122P - Response to Metabolically Supported Chemotherapy (MSCT) with weekly Carboplatin/Paclitaxel in Advanced Stage /Metastatic (Stage IV) Non-Small Cell Lung Cancer: A Survival, Efficacy and Tolerability Analysis
M.S. Iyikesici, A. Slocum, A.K. Slocum, E. Turkmen, F.B. Berkarda; TR
- 12:30 - 12:30 123P - A retrospective study in Chinese patients: Is there a role of Nanoparticle Albumin Bound Paclitaxel in advanced NSCLC?
Y. Zhu, P. Xing, L. Shan, S. Chen, X. Hao, J. Li; CN
- 12:30 - 12:30 124P - Driverless lung carcinoma: Impact of expanded RNA and protein-based testing on detection of actionable biomarkers
Z. Gatalica¹, J. Xiu¹, W. Chen¹, T. Maney¹, A. Voss², N. Plowman³; ¹AZ/US, ²CH, ³GB
- 12:30 - 12:30 125P - Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): a prospective German Registry in stage IV NSCLC, AIO-TRK-0315
F. Griesinger, W. Eberhardt, N. Marschner, M. Jänicke, A. Fleitz, J. Sahlmann, A. Karatas, A. Hipper, M. Sebastian, M. Thomas; DE
- 12:30 - 12:30 126P - The Clinical Impact of Multiplex ctDNA Gene Analysis in Lung Cancer
S. Geva¹, T. Twito¹, A. Dvir¹, L. Soussan-Gutman¹, M. Ilouze¹, L. Roisman¹, E. Dudnik¹, A. Zer¹, R. Lanman², N. Peled¹; ¹IL, ²CA/US



- 12:30 - 12:30 127P - Prognostic Significance of Advanced Lung Cancer Inflammation Index (ALI) In Untreated and Treated Stage IV Non-Small Cell Lung Cancer (NSCLC): An Australian Cancer Centre Experience
H. Mandaliya¹, M. Jones¹, C. Oldmeadow², I. Nordman¹; ¹NSW/AU, ²AU
- 12:30 - 12:30 128P - serum DKK-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases
R. Qiao, T. Chu, B. Han, R. Zhong, Q. Chang, J. Teng, J. Pei; CN
- 12:30 - 12:30 129P - Procathepsin D as a novel diagnostic marker for malignant pleural effusion of lung cancer
C.Y. Lee, J.Y. Hong, M.-G. Lee, S.H. Jang; KR
- 12:30 - 12:30 130P - EGFR mutations in lung adenocarcinoma and brain metastases: a Croatian single institution experience.
K. Sreter, S. Kukulj, S. Smojver-Jezek, S. Seiwerth, M. Jakopovic, M. Samarzija; HR
- 12:30 - 12:30 131P - T790M co-exists with other secondary resistance mechanisms in EGFR mutation positive NSCLC and are associated with inferior outcomes
R. Teng, A. Takano, W.-L. Tan, M.-K. Ang, C.-K. Toh, Q.-S. Ng, W.-T. Lim, E.-H. Tan, T. Lim, D. Tan; SG
- 12:30 - 12:30 132P - Real world treatment patterns and outcomes for mNSCLC patients receiving second- and third-line therapy in Germany
N. Yu¹, I. Reyes-Rivera², J. Hipp³, M. Zou², N. Pillai², S. Hammerschmidt³; ¹GB, ²CH, ³DE
- 12:30 - 12:30 133P - The influence of body composition on TTFIELDS intensity in the lungs
U. Weinberg¹, N. Urman², H. Hershkovich², Z. Bomzon², E. Kirson², Y. Palti²; ¹CH, ²IL
- 12:30 - 12:30 134P - Applicable CT-guided percutaneous radiofrequency ablationRFAin the treatment of unresectable Lung Ground Glass OpacityGGO
Y. Wei, CN
- 12:30 - 12:30 135P - Cocksackievirus type B3 is a potent oncolytic virus against KRAS-mutant non-small-cell lung cancer
H. Deng, T. Sliva, Y. Xue, Y. Mohamud, J. Zhang, W. Lockwood, H. Luo; BC/CA
- 12:30 - 12:30 136P - Long-Term Safety and Efficacy of Darbepoetin alfa in Subjects With Stage IV NSCLC Receiving Multi-Cycle Chemotherapy
P. Gascón¹, R. Nagarkar², M. Šmakal³, K. Syrigos⁴, C. Barrios⁵, J. Cárdenas Sánchez⁶, L. Zhang⁷, D. Henry⁸, D. Tomita⁹, C. De Oliveira Brandao⁹; ¹ES, ²IN, ³CZ, ⁴GR, ⁵BR, ⁶MX, ⁷CN, ⁸PA/US, ⁹CA/US
- 12:30 - 12:30 137P - Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy
M. Pignata¹, K. Le Lay¹, L. Luciani¹, C. McConnachie², J. Gordon³, C. Chouaid¹, S. Roze¹; ¹FR, ²CH, ³DE
- 12:30 - 12:30 138TiP - An Open-label Phase 3b/4 Safety Trial of Flat-Dose Nivolumab Plus Ipilimumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)



L. Paz-Ares¹, B. Lash², I. Albert³, G. Gagnon⁴, C. Chakmakjian⁵, N. Ready⁶, W. Hu⁷, L. Krug⁷, J. Fairchild⁷, R.N. Pillai⁸; ¹ES, ²PA/US, ³HU, ⁴QC/CA, ⁵TX/US, ⁶NC/US, ⁷NJ/US, ⁸GA/US

12:30 - 12:30 139TiP - A non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib according to the approved label (LUME-BioNIS)

M. Reck¹, A.J. Staal-Van den Brekel², A. Mellema³, N. Morsli⁴, A.-M. Ellingboe⁵, R. Kaiser¹, K. Pietzko¹, T. Kitzing¹, J. Braunger¹, K. Kerr⁶; ¹DE, ²NL, ³DK, ⁴FR, ⁵NO, ⁶GB

12:30 - 12:30 140TiP - CheckMate 384: A Phase 3b/4 Dose-Frequency Optimization Trial of Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

N. Reinmuth¹, R. Harris², P. Mitchell³, E.B. Garon⁴, J. Zhu⁵, I.-F. Chang⁵, E. Pichon⁶; ¹DE, ²NY/US, ³VIC/AU, ⁴CA/US, ⁵NJ/US, ⁶FR

12:30 - 12:30 141TiP - ASTRIS: A Multicenter, Real World Treatment Study of osimertinib in EGFR T790M Positive Non-Small Cell Lung Cancer (NSCLC)

P. Cheema¹, Y.-M. Chen², F. de Marinis³, H. Freitas⁴, S.-W. Kim⁵, A. Milner⁶, M. Provencio⁷, J. Rigas⁶, Y.-L. Wu⁸; ¹CA, ²TW, ³IT, ⁴BR, ⁵KR, ⁶GB, ⁷ES, ⁸CN

12:30 - 12:30 142TiP - A Prospective Multi-center Study to Investigate the EGFR-TKI Resistance Profile, Treatment Algorithm and Clinical Outcome in Chinese Patients with Advanced EGFRm+ NSCLC Who Have Received Prior First Generation EGFR TKI (PRECENT study, CCTC-1601, NCT02988141)

W. Liang, L. Wu, L. Wang, Y. Huang, R. Xu, L. Zhang, J. He; CN

12:30 - 12:30 143TiP - IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naïve NSCLC

J. Jassem¹, F. de Marinis², D. Spigel³, S. Lam⁴, S. Mocchi⁴, A. Sandler⁴, A. Lopez-Chavez⁴, Y. Deng⁴, G. Giaccone⁵, R. Herbst⁶; ¹PL, ²IT, ³TN/US, ⁴CA/US, ⁵US, ⁶CT/US

12:30 - 12:30 144TiP - CheckMate 227: A Randomized, Open-label Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Nivolumab Plus Chemotherapy Versus Chemotherapy in Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

L. Paz-Ares¹, J. Brahmer², M.D. Hellmann³, M. Reck⁴, K. O'Byrne⁵, H. Borghaei⁶, W. Geese⁷, H. Lu⁷, F.E. Nathan⁷, S. Ramalingam⁸; ¹ES, ²MD/US, ³NY/US, ⁴DE, ⁵QLD/AU, ⁶PA/US, ⁷NJ/US, ⁸GA/US

12:30 - 12:30 145TiP - TTFIELDS combined with PD-1 inhibitors or docetaxel for 2nd Line Treatment of non-small-cell lung cancer (NSCLC): Phase 3 LUNAR study

U. Weinberg¹, O. Farber¹, M. Giladi², Z. Bomzon², E. Kirson²; ¹CH, ²IL

12:30 - 12:30 146TiP - eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

L. Horn¹, Y.-L. Wu², M. Reck³, C. Liang⁴, F. Tan², K. Harrow⁴, V. Oertel⁴, G. Dukart⁴, T.S.K. Mok²; ¹US, ²CN, ³DE, ⁴FL/US

12:30 - 12:30 Metastases to and from the lung



- 12:30 - 12:30 148P - Metastatic site location may influence the diagnostic accuracy of plasma EGFR-mutation testing in NSCLC: a pooled analysis
F. Passiglia¹, A. Listi¹, N. Barraco¹, A. Galvano¹, D. Fanale¹, L. Incorvaia¹, V. Bazan¹, C. Rolfo², A. Russo¹; ¹IT, ²BE
- 12:30 - 12:30 149P - PD-L1 expression patterns in the metastatic tumors to the lung: a comparative study with the primary non-small cell lung cancer
Z. Gatalica¹, J. Senarathne¹, S. Vranic²; ¹AZ/US, ²BA
- 12:30 - 12:30 150P - Immunohistochemical characteristics of brain metastases and corresponding primary lung cancer
D. Marinova, Y. Slavova, S. Nachev, D. Dimitrova, E. Mekov, M. Mihailov, D. Kostadinov, V. Youroukova; BG
- 12:30 - 12:30 151P - Predictors of Survival in Patients with Bone Metastasis of Lung Cancer
S. Jagadeesan, IN
- 12:30 - 12:30 152P - Relationship between overall survival and preoperative parameters in patients with colorectal cancer and synchronous liver and lung metastases
F. Lumachi, S. Basso, U. Zuccon, F. Maffei, A. Del Conte, P. Ubiali; IT
- 12:30 - 12:30 153P - Predictive markers of survival in patients with pulmonary metastases and malignant pleural effusion
F. Lumachi, S. Basso, R. Tozzoli, A. Del Conte, U. Zuccon, P. Ubiali; IT
- 12:30 - 12:30 154P - Analysis of factors affecting survival in patients with simultaneous liver and pulmonary metastases from colorectal cancer
F. Lumachi, S. Basso, U. Zuccon, F. Maffei, A. Del Conte, P. Ubiali; IT
- 12:30 - 12:30 155P - Combination of hepatic surgery and minimally invasive thoracic surgery using a subxyphoid approach through an abdominal incision.
M. Lim, D.H. Kim; KR
- 12:30 - 12:30 156P - Clinical outcome of Cyberknife radiosurgery in brain metastases of non-small cell lung cancer: a single institutional experience
S.-W. Lee, Y.-S. Kim, Y.K. Won, S.J. Lee, J.H. Hong, Y.N. Kang, J.H. Kang, S.-H. Hong, S.J. Kim, Y.K. Kim; KR
- 12:30 - 12:30 157P - Mediastinal masses: A study of our cases by transthoracic needle biopsy(TTNB) versus open surgery as a diagnostic procedure.
F. Gradica, L. Lisha, D. Argjiri, A. Cani, A. Leka, F. Kokici, S. Gradica, Y. Vata, F. Gradica, V. Rexha; AL
- 12:30 - 12:30 158TiP - Open Label, Multi-center, Prospective Study to Investigate the Efficacy and Safety of Osimertinib in Brain Metastases from Patients with EGFR T790M Positive NSCLC Who Have Received Prior Therapy with an EGFR-TKI (APOLLO Study, NCT02972333)
L. Wang, L. Xing, L. Cao, L. Wang, X. Wang, J. Feng, Y. Shu, Y. Shi, Y. Song, J. Yu; CN
- 12:30 - 12:30 159TiP - TTFIELDS and radiosurgery for 1-10 brain metastases from NSCLC: The Phase 3 METIS study
M. Mehta¹, V. Gondi², P. Brown³; ¹FL/US, ²IL/US, ³MN/US



- 12:30 - 12:30 Mesothelioma
- 12:30 - 12:30 160P - BAP1 in advanced sporadic malignant pleural mesothelioma
A. El Bastawisy, R. Shehab, A. Bahnassy, N. Sabri; EG
- 12:30 - 12:30 161P - Dkk1 stabilization as a new malignant pleural mesothelioma therapeutic avenue.
A. Guazzelli, E. Bakker, F. Sotgia, M. Listanti, M. Krstic-Demonacos, L. Mutti; GB
- 12:30 - 12:30 162P - Targeting the RON/MET/TAM signalling network in mesothelioma
A.-M. Baird¹, M. Jarzabek¹, L. Shiels¹, S. Raeppl², S. Finn¹, S. Cuffe¹, H. Pass³, I. Schmitt-Opitz⁴, A. Byrne¹, S. Gray¹; ¹IE, ²CA, ³US, ⁴CH
- 12:30 - 12:30 164P - Heart radiation dose as a risk factor for dyspnea worsening after multimodality treatment for Non-Small Cell Lung Cancer and Pleural Mesothelioma : an exploratory analysis
A. Botticella¹, C. Billiet¹, G. Defraene¹, C. Draulans¹, K. Nackaerts¹, C. Deroose¹, J. Coolen¹, P. Nafteux¹, D. De Ruyscher²; ¹BE, ²NL
- 12:30 - 12:30 165P - Malignant pleural mesothelioma: a systematic review of first-line chemotherapy and analysis of Hong Kong cohort
H. Pang, J. Ji, K. Yan, C.C. Leung, D. Lam; CN
- 12:30 - 12:30 166P - Thymoma and thymic carcinoma: a real-life retrospective analysis
I. Attili, S. Frega, A. Pavan, G. Pasello, V. Polo, G. Zago, F. Rea, F. Calabrese, P. Conte, L. Bonanno; IT
- 12:30 - 12:30 167P - Role of surgery in the treatment of thymic carcinoma based on a 5-year experience
F. Caushi, I. Skenduli, J. Shkurti, D. Xhemalaj, A. Hatibi, R. Kortoci, B. Gega, H. Hafizi; AL
- 12:30 - 12:30 168P - Clinical and prognostic characteristics of primary pulmonary non-Hodgkin's lymphoma: a retrospective analysis of 38 cases in a Chinese population
R. Qiao, B. Han, R. Zhong, Y. Zhao, T. Chu, L. Jiang, H. Zhong; CN
- 12:30 - 12:30 169P - Pulmonary carcinoid tumors: experience from an oncology center
L. Bei, A. Silva, A.L. Cunha, C. Franco, J. Oliveira, I. Azevedo, I. Pousa, A. Rodrigues, M. Soares, D. Pereira; PT
- 12:30 - 12:30 170TiP - LUME-Meso: Randomised Phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM)
S. Popat¹, R. Gaafar², A. Nowak³, A. Tsao⁴, J. Van Meerbeeck⁵, N. Vogelzang⁶, T. Nakano⁷, D. Velema⁸, N. Morsli⁹, G. Scagliotti¹⁰; ¹GB, ²EG, ³WA/AU, ⁴TX/US, ⁵BE, ⁶US, ⁷JP, ⁸ON/CA, ⁹FR, ¹⁰IT

13:00 - 14:00 Industry Satellite Symposium 6

Room A



13:00 - 14:00	Industry Satellite Symposium 7	Room C
14:10 - 14:40	Keynote lecture: Molecular clonal development of lung cancer Chair: A. Nicholson, GB	Room B
14:10 - 14:40	Molecular clonal development of lung cancer <u>C. Swanton</u> , GB	
14:45 - 16:15	Patient with early stage disease and compromised lung function Chair: A.-M. Dingemans, NL	Room A
14:45 - 15:15	Patient assessment and shared decision-making <u>D.R. Baldwin</u> , GB	
15:15 - 15:45	The case for limited surgery <u>A.D.L. Sihoe</u> , CN	
15:45 - 16:15	The argument for SBRT <u>K. Franks</u> , GB	
14:45 - 16:15	Malignant pleural mesothelioma Chair: J. Van Meerbeeck, BE; D. Waller, GB	Room C
14:45 - 15:05	Genetics of mesothelioma <u>M. Carbone</u> , US	
15:05 - 15:25	Prognostic indices <u>I. Opitz</u> , CH	
15:25 - 15:45	Surgical approach: P/D versus EPP <u>D. Waller</u> , GB	
15:45 - 16:05	Combined modality therapy <u>J. Van Meerbeeck</u> , BE	
16:05 - 16:15	Questions and Answers	



14:45 - 15:45	Targeted therapies and immunotherapies	Room W
14:45 - 14:45	<p>89PD - Results from OAK subgroup analyses: a randomized Phase III study of atezolizumab vs docetaxel in patients (pts) with advanced NSCLC</p> <p><u>D. Cortinovis</u>¹, S. Gadgeel², A. Rittmeyer³, F. Barlesi⁴, M. Cobo Dols⁵, T. Hida⁶, P. He⁷, M. Ballinger⁷, D. Gandara⁷, J. von Pawel³; ¹IT, ²MS/US, ³DE, ⁴FR, ⁵ES, ⁶JP, ⁷CA/US</p>	
14:45 - 14:45	<p>90PD - Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): efficacy and safety data</p> <p><u>R. Herbst</u>¹, J. Martin-Liberal², E. Calvo², N. Isambert³, J. Bendell⁴, P. Cassier³, J. Jin⁵, G. Mi⁶, J. Rege⁵, L. Paz-Ares²; ¹CT/US, ²ES, ³FR, ⁴TN/US, ⁵NJ/US, ⁶IN/US</p>	
14:45 - 14:45	<p>91PD - Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC</p> <p><u>S. Rothschild</u>¹, P. Leger², E.L. Castellanos², R.N. Pillai³, S.J. York², L. Horn²; ¹CH, ²US, ³GA/US</p>	
14:45 - 15:00	Invited Discussant 89PD, 90PD and 91PD	
15:00 - 15:15	Discussion	
15:15 - 15:15	<p>92PD - First-line afatinib for advanced EGFRm+ NSCLC: analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials</p> <p><u>M. Schuler</u>¹, L. Paz-Ares², L. Sequist³, Y.-L. Wu⁴, S. Geater⁵, A. Märten¹, J. Fan⁶, K. Park⁷, J.C.-H. Yang⁸; ¹DE, ²ES, ³MA/US, ⁴CN, ⁵TH, ⁶CT/US, ⁷KR, ⁸TW</p>	
15:15 - 15:15	<p>93PD - Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)</p> <p><u>J. Corral</u>¹, K. Park², J.C.-H. Yang³, T. Mok⁴, E.-H. Tan⁵, K. O'Byrne⁶, V. Hirsh⁷, M. Boyer⁶, J. Fan⁸, L. Zhang⁴; ¹ES, ²KR, ³TW, ⁴CN, ⁵SG, ⁶NSW/AU, ⁷QC/CA, ⁸CT/US</p>	
15:15 - 15:15	<p>94PD - Adverse events self-reported by patients with advanced non-small-cell lung cancer treated with osimertinib or chemotherapy</p> <p><u>M. Sebastian</u>¹, A. Ryden², A. Walding³, S. Giorghiu³, K. Rüdell³, V. Papadimitrakopoulou⁴; ¹DE, ²SE, ³GB, ⁴TX/US</p>	
15:15 - 15:30	<p>Invited Discussant 92PD, 93PD and 94PD</p> <p><u>N. Reguart</u>, ES</p>	
15:30 - 15:45	Discussion	
16:15 - 16:45	Coffee break	Hall 1



16:45 - 18:15	ESMO-IASLC Best Abstracts Chair: M. Reck, DE; A. Nicholson, GB	Room B
16:45 - 17:00	81O - Safety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases <u>R. Lukas</u> ¹ , M. Gandhi ² , C. O'hear ² , S. Hu ² , C. Lai ² , J. Patel ¹ ; ¹ IL/US, ² CA/US	
17:00 - 17:15	82O - Durvalumab in ≥3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: results from the Phase 2 ATLANTIC study <u>M. Garassino</u> ¹ , B.-C. Cho ¹ , J. Gray ² , J. Mazières ³ , K. Park ¹ , R. Soo ⁴ , P. Dennis ⁵ , Y. Huang ⁵ , C. Wadsworth ⁶ , N. Rizvi ⁷ ; ¹ KR, ² FL/US, ³ FR, ⁴ SG, ⁵ MD/US, ⁶ GB, ⁷ US	
17:15 - 17:30	Invited Discussant 81O and 82O <u>S. Peters</u> , CH	
17:30 - 17:45	147O - Correlation of molecular status and anatomic sites of metastases (mets) at diagnosis (Dx) of non-small cell lung cancer (NSCLC) <u>C. Kuijpers</u> , L. Hendriks, J. Derks, A.-M. Dingemans, A. Van Lindert, M. Van den Heuvel, R. Damhuis, S. Willems; NL	
17:45 - 18:00	One LBA TBC	
18:00 - 18:15	Invited Discussant 147O and one LBA TBC <u>A. Nicholson</u> , GB	



16:45 - 18:15	4th ESO Lung Cancer Observatory: Innovation and care in the next 12 months Chair: M. Aapro, CH; E. Felip, ES	Room W
16:45 - 16:55	Prevention: Are we progressing in anti-tobacco campaigns in the world? <u>C. Adams</u> , CH	
16:55 - 17:05	Screening: Where will it be in 2018? <u>H. de Koning</u> , NL	
17:05 - 17:15	Surgery or radiation: When is it a choice? <u>U. Pastorino</u> , IT	
17:15 - 17:25	Radiation oncology: Will guidelines change? <u>F. Mornex</u> , FR	
17:25 - 17:35	What to ask your pathologist today and in 2018? <u>K. Kerr</u> , GB	
17:35 - 17:45	Developments in medical oncology: What practice changing studies will mature in 2018? <u>E. Felip</u> , ES	
17:45 - 17:55	The patient's perspective <u>F. Johansson</u> , AF	
17:55 - 18:15	Panel discussion	
18:40 - 19:40	Industry Satellite Symposium 8	Room A
18:40 - 19:40	Industry Satellite Symposium 9	Room C

08-05-2017



11:20 - 12:50	ESMO recommendations Chair: M. Frueh, CH; S. Novello, IT	Room A
11:20 - 11:40	NSCLC <u>S. Novello</u> , IT	
11:40 - 12:00	SCLC <u>M. Frueh</u> , CH	
12:00 - 12:20	Mesothelioma <u>P. Baas</u> , NL	
12:20 - 12:40	Thymic <u>N. Girard</u> , FR	
12:40 - 12:50	Questions and Answers	
12:50 - 13:00	Closing remarks Chair: M. Reck, DE; A. Nicholson, GB	Room A